1
|
Matte P, Rousseau A, Courtier B, Duval M, Laune Q, Duval J, Kfoury M, Delaye M. Perspectives of oncology residents on Master's Degree in Science (MSc) programs: a national descriptive study by the French Association of Residents in Oncology (AERIO). ESMO Open 2024; 9:103445. [PMID: 38669772 PMCID: PMC11061220 DOI: 10.1016/j.esmoop.2024.103445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Revised: 04/03/2024] [Accepted: 04/04/2024] [Indexed: 04/28/2024] Open
Affiliation(s)
- P Matte
- Association d'enseignement et de recherche des internes en oncologie (AERIO), Paris; Laboratoire de Recherche Translationnelle en Immunothérapie (LRTI), INSERM U1015, Villejuif.
| | - A Rousseau
- Association d'enseignement et de recherche des internes en oncologie (AERIO), Paris; Department of Cancer Medicine, Gustave Roussy, Thoracic Group and International Center for Thoracic Cancers (CICT), Paris-Saclay University, Villejuif
| | - B Courtier
- Association d'enseignement et de recherche des internes en oncologie (AERIO), Paris; Medical Oncology Department, Institut Curie, Paris
| | - M Duval
- Association d'enseignement et de recherche des internes en oncologie (AERIO), Paris; Medical Oncology Department, Institut Curie, Versailles Saint-Quentin University, Saint-Cloud
| | - Q Laune
- Association d'enseignement et de recherche des internes en oncologie (AERIO), Paris
| | - J Duval
- Association d'enseignement et de recherche des internes en oncologie (AERIO), Paris
| | - M Kfoury
- Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France
| | - M Delaye
- Association d'enseignement et de recherche des internes en oncologie (AERIO), Paris; Medical Oncology Department, Institut Curie, Versailles Saint-Quentin University, Saint-Cloud
| |
Collapse
|
2
|
Gewirtz-Meydan A, Koós M, Nagy L, Kraus SW, Demetrovics Z, Potenza MN, Ballester-Arnal R, Batthyány D, Bergeron S, Billieux J, Burkauskas J, Cárdenas-López G, Carvalho J, Castro-Calvo J, Chen L, Ciocca G, Corazza O, Csako R, Fernandez DP, Fujiwara H, Fernandez EF, Fuss J, Gabrhelík R, Gjoneska B, Gola M, Grubbs JB, Hashim HT, Islam MS, Ismail M, Jiménez-Martínez MC, Jurin T, Kalina O, Klein V, Költő A, Lee SK, Lewczuk K, Lin CY, Lochner C, López-Alvarado S, Lukavská K, Mayta-Tristán P, Miller DJ, Orosová O, Orosz G, Ponce FP, Quintana GR, Quintero Garzola GC, Ramos-Diaz J, Rigaud K, Rousseau A, De Tubino Scanavino M, Schulmeyer MK, Sharan P, Shibata M, Shoib S, Sigre-Leirós V, Sniewski L, Spasovski O, Steibliene V, Stein DJ, Strong C, Ünsal BC, Vaillancourt-Morel MP, Van Hout MC, Bőthe B. Global cross-cultural validation of a brief measure for identifying potential suicide risk in 42 countries. Public Health 2024; 229:13-23. [PMID: 38382177 DOI: 10.1016/j.puhe.2023.12.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2023] [Revised: 12/11/2023] [Accepted: 12/29/2023] [Indexed: 02/23/2024]
Abstract
OBJECTIVES This study aimed to examine the psychometric properties of the P4 suicide screener in a multinational sample. The primary goal was to evaluate the reliability and validity of the scale and investigate its convergent validity by analyzing its correlation with depression, anxiety, and substance use. STUDY DESIGN The study design is a cross-sectional self-report study conducted across 42 countries. METHODS A cross-sectional, self-report study was conducted in 42 countries, with a total of 82,243 participants included in the final data set. RESULTS The study provides an overview of suicide ideation rates across 42 countries and confirms the structural validity of the P4 screener. The findings indicated that sexual and gender minority individuals exhibited higher rates of suicidal ideation. The P4 screener showed adequate reliability, convergence, and discriminant validity, and a cutoff score of 1 is recommended to identify individuals at risk of suicidal behavior. CONCLUSIONS The study supports the reliability and validity of the P4 suicide screener across 42 diverse countries, highlighting the importance of using a cross-cultural suicide risk assessment to standardize the identification of high-risk individuals and tailoring culturally sensitive suicide prevention strategies.
Collapse
Affiliation(s)
- A Gewirtz-Meydan
- School of Social Work, Faculty of Social Welfare and Health Sciences, University of Haifa, Israel. Agewirtz-@univ.haifa.ac.il
| | - M Koós
- Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Institute of Forensic Psychiatry and Sex Research, University of Duisburg-Essen, Essen, Germany
| | - L Nagy
- Doctoral School of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary
| | - S W Kraus
- Department of Psychology, University of Nevada, Las Vegas, Las Vegas, NV, USA
| | - Z Demetrovics
- Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Centre of Excellence in Responsible Gaming, University of Gibraltar, Gibraltar, Gibraltar
| | - M N Potenza
- Yale University School of Medicine, New Haven, CT, USA; Connecticut Council on Problem Gambling, Wethersfield, CT, USA
| | - R Ballester-Arnal
- Departmento de Psicología Básica, Clínica y Psicobiología, University Jaume I of Castellón, Spain
| | - D Batthyány
- Institute for Behavioural Addictions, Sigmund Freud University Vienna, Austria
| | - S Bergeron
- Département de Psychologie, Université de Montréal, Montréal, Canada
| | - J Billieux
- Institute of Psychology, University of Lausanne, Lausanne, Switzerland; Center for Excessive Gambling, Addiction Medicine, Lausanne University Hospitals (CHUV), Lausanne, Switzerland
| | - J Burkauskas
- Laboratory of Behavioral Medicine, Neuroscience Institute, Lithuanian University of Health Sciences, Lithuania
| | - G Cárdenas-López
- Virtual Teaching and Cyberpsychology Laboratory, School of Psychology, National Autonomous University of Mexico, Mexico
| | - J Carvalho
- William James Center for Research, Departamento de Educação e Psicologia, Universidade de Aveiro, Aveiro, Portugal
| | - J Castro-Calvo
- Department of Personality, Assessment, and Psychological Treatments, University of Valencia, Spain
| | - L Chen
- Department of Psychology, College of Humanity and Social Science, Fuzhou University, China
| | - G Ciocca
- Section of Sexual Psychopathology, Department of Dynamic and Clinical Psychology, and Health Studies, Sapienza University of Rome, Rome, Italy
| | - O Corazza
- Department of Clinical, Pharmaceutical and Biological Sciences, University of Hertfordshire, UK; Department of Psychology and Cognitive Science, University of Trento, Italy
| | - R Csako
- Department of Psychology and Neuroscience, Auckland University of Technology, Auckland, New Zealand
| | | | - H Fujiwara
- Department of Neuropsychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Decentralized Big Data Team, RIKEN Center for Advanced Intelligence Project, Tokyo, Japan
| | | | - J Fuss
- Institute of Forensic Psychiatry and Sex Research, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen, Essen, Germany
| | - R Gabrhelík
- Charles University, First Faculty of Medicine, Department of Addictology, Prague, Czech Republic; General University Hospital in Prague, Department of Addictology, Czech Republic
| | - B Gjoneska
- Macedonian Academy of Sciences and Arts, Macedonia
| | - M Gola
- Institute of Psychlogy, Polish Academy of Sciences, Poland; Institute for Neural Computations, University of California San Diego, USA
| | - J B Grubbs
- University of New Mexico, Albuquerque, USA; Center for Alcohol, Substance Use, And Addiction (CASAA), University of New Mexico, Albuquerque, USA
| | - H T Hashim
- University of Baghdad, College of Medicine, Iraq
| | - M S Islam
- Department of Public Health and Informatics, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh; Centre for Advanced Research Excellence in Public Health, Savar, Dhaka 1342, Bangladesh
| | - M Ismail
- University of Baghdad, College of Medicine, Iraq
| | - M C Jiménez-Martínez
- Universidad Pedagógca y Tecnológica de Colombia, Colombia; Grupo de Investigación Biomédica y de Patología, Colombia
| | - T Jurin
- Department of Psychology, Humanities and Social Sciences, University of Zagreb, Croatia
| | - O Kalina
- Department of Educational Psychology and Psychology of Health, Pavol Jozef Safarik University in Kosice, Slovakia
| | - V Klein
- School of Psychology, University of Southampton, UK
| | - A Költő
- Health Promotion Research Centre, University of Galway, Ireland, UK
| | - S-K Lee
- Department of Psychiatry, Hallym University Chuncheon Sacred Heart Hospital, South Korea; Chuncheon Addiction Management Center, South Korea
| | - K Lewczuk
- Institute of Psychology, Cardinal Stefan Wyszynski University, Warsaw, Poland
| | - C-Y Lin
- Institute of Allied Health Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - C Lochner
- SAMRC Unit on Risk & Resilience in Mental Disorders, Stellenbosch University, South Africa
| | | | - K Lukavská
- Charles University, First Faculty of Medicine, Department of Addictology, Prague, Czech Republic; Charles University, Faculty of Education, Department of Psychology, Prague, Czech Republic
| | - P Mayta-Tristán
- Facultad de Medicina, Universidad Científica del Sur, Lima, Peru
| | - D J Miller
- College of Healthcare Sciences, James Cook University, Australia
| | - O Orosová
- Pavol Jozef Safarik University in Kosice, Department of Educational Psychology and Psychology of Health, Slovakia
| | | | - F P Ponce
- Facultad de Psicología, Universidad de Talca, Chile
| | - G R Quintana
- Departamento de Psicología y Filosofía, Facultad de Ciencias Sociales, Universidad de Tarapacá, Arica, Arica y Parinacota, Chile
| | - G C Quintero Garzola
- Florida State University, Panama; Sistema Nacional de Investigación (SNI), SENACYT, Panama
| | - J Ramos-Diaz
- Facultad de Ciencias de la Salud, Universidad Privada del Norte, Lima, Perú
| | | | - A Rousseau
- Leuven School for Mass Communication, KU Leuven, Leuven, Belgium
| | - M De Tubino Scanavino
- Department of Psychiatry, Faculdade de Medicina, Universidade de São Paulo, Brazil; Experimental Pathophisiology Post Graduation Program, Faculdade de Medicina, Universidade de São Paulo, Brazil
| | | | - P Sharan
- Department of Psychiatry, All India Institute of Medical Sciences, New Delhi, 110029, India
| | - M Shibata
- Department of Neuropsychiatry, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - S Shoib
- Department of Psychology, Shardha University, India; Department of Health Kashmir, India
| | - V Sigre-Leirós
- Institute of Psychology, University of Lausanne, Lausanne, Switzerland; Institute of Legal Psychiatry, Lausanne University Hospitals (CHUV), Lausanne, Switzerland
| | - L Sniewski
- Auckland University of Technology, New Zealand
| | - O Spasovski
- Faculty of Philosophy, Ss. Cyril and Methodius University in Skopje, Macedonia; Faculty of Philosophy, University of Ss. Cyril and Methodius in Trnava, Slovakia
| | - V Steibliene
- Laboratory of Behavioral Medicine, Neuroscience Institute, Lithuanian University of Health Sciences, Lithuania
| | - D J Stein
- SAMRC Unit on Risk & Resilience in Mental Disorders, Dept of Psychiatry & Neuroscience Institute, University of Cape Town, South Africa
| | - C Strong
- Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - B C Ünsal
- Doctoral School of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary; Institute of Psychology, ELTE Eötvös Loránd University, Budapest, Hungary
| | - M-P Vaillancourt-Morel
- Département de Psychologie, Université du Québec à Trois-Rivières, Trois-Rivières, Canada
| | - M C Van Hout
- Public Health Institute, Faculty of Health, Liverpool John Moores University, UK
| | - B Bőthe
- Département de Psychologie, Université de Montréal, Montréal, Canada; Département de Psychologie, Université du Québec à Trois-Rivières, Trois-Rivières, Canada
| |
Collapse
|
3
|
Labbé A, Rousseau A, Denis P, Bresson-Dumont H, Baudouin C, Aptel F. [Review by the French Glaucoma Society on the roles of new surgical techniques in glaucoma]. J Fr Ophtalmol 2023; 46:1227-1231. [PMID: 37945427 DOI: 10.1016/j.jfo.2023.08.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2023] [Accepted: 08/31/2023] [Indexed: 11/12/2023]
Abstract
The surgical management of glaucoma has been enriched in recent years by the arrival of new surgical techniques as a group known as MIGS (minimally invasive glaucoma surgery). The objective of these new techniques is to reduce intraocular pressure (IOP) while limiting the risk of complications of conventional filtering surgery and allowing faster visual recovery. MIGS can be classified into three main categories depending on the route used to promote the outflow of aqueous humor: the trabecular route, the suprachoroidal route and the subconjunctival route. MIGS using the subconjunctival route are also called minimally invasive bleb surgery (MIBS). These new techniques do not replace conventional filtering surgery, which remains the gold standard technique, but now offer new alternatives for the surgical management of glaucoma patients in combination with cataract surgery or as stand-alone procedures.
Collapse
Affiliation(s)
- A Labbé
- Service d'ophtalmologie, CHNO des Quinze-Vingts, IHU FOReSight, Paris, France; Service d'ophtalmologie, hôpital Ambroise-Paré, AP-HP, IHU FOReSIGHT, université de Versailles Saint-Quentin-en-Yvelines, Boulogne Billancourt, France.
| | - A Rousseau
- Service d'ophtalmologie, hôpital Bicêtre, AP-HP, IHU FOReSIGHT, université Paris Saclay, Le Kremlin-Bicêtre, France
| | - P Denis
- Service d'ophtalmologie, hôpital de la Croix-Rousse, Lyon, France
| | | | - C Baudouin
- Service d'ophtalmologie, CHNO des Quinze-Vingts, IHU FOReSight, Paris, France; Service d'ophtalmologie, hôpital Ambroise-Paré, AP-HP, IHU FOReSIGHT, université de Versailles Saint-Quentin-en-Yvelines, Boulogne Billancourt, France
| | - F Aptel
- Groupe Visis, médipôle Elsan, Perpignan, France
| |
Collapse
|
4
|
Rousseau A, Stien C, Gouriou J, Bordy JM, Boissonnat G, Chabert I, Dufreneix S, Blideanu V. End-to-end quality assurance for stereotactic radiotherapy with Fricke-Xylenol orange-Gelatin gel dosimeter and dual-wavelength cone-beam optical CT readout. Phys Med 2023; 113:102656. [PMID: 37625218 DOI: 10.1016/j.ejmp.2023.102656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 06/04/2023] [Accepted: 08/05/2023] [Indexed: 08/27/2023] Open
Abstract
PURPOSE The end-to-end (E2E) quality assurance (QA) test is a unique tool for validating the treatment chain undergone by patients in external radiotherapy. It should be conducted in three dimensions (3D) to get accurate results. This study aims to implement these tests with Fricke-Xylenol orange-Gelatin (FXG) gel dosimeter and a newly developed dual-wavelength reading method on the Vista16™ optical Computed Tomography (CT) scanner (ModusQA) for three treatment techniques in stereotactic radiotherapy, on Novalis (Varian) and CyberKnife (Accuray) linear accelerators. METHODS The tests were performed in head phantoms. Gel measurements were compared with planned dose distributions and measured by film and ion chamber measurements by plotting isodose curves and dose profiles, and by conducting a 3D local gamma-index analysis (2%/2mm criteria). RESULTS Gamma passing rates were higher than 95 %. Point dose differences between treatment planning and gel and ion chamber measurements at the isocenter were < 2.3 % for both treatments delivered on the Novalis accelerator, while this difference was higher than 4 % for the treatment delivered on the CyberKnife, highlighting a small overdosing of the tumor volume. A good agreement was observed between gel and film dose profiles. CONCLUSIONS This study presents the successful implementation of 3D E2E QA tests for stereotactic radiotherapy with FXG gel dosimetry and a dual-wavelength reading method on an optical CT scanner. This dosimetric method provides 3D absolute dose distributions in the 0.25 - 10 Gy dose range with a high spatial resolution and a dose uncertainty of around 2 % (k=1).
Collapse
Affiliation(s)
- Alice Rousseau
- Université Paris-Saclay, CEA, List, Laboratoire National Henri Becquerel (LNE-LNHB), Palaiseau, France.
| | - Christel Stien
- Université Paris-Saclay, CEA, List, Laboratoire National Henri Becquerel (LNE-LNHB), Palaiseau, France
| | - Jean Gouriou
- Université Paris-Saclay, CEA, List, Laboratoire National Henri Becquerel (LNE-LNHB), Palaiseau, France
| | - Jean-Marc Bordy
- Université Paris-Saclay, CEA, List, Laboratoire National Henri Becquerel (LNE-LNHB), Palaiseau, France
| | - Guillaume Boissonnat
- Université Paris-Saclay, CEA, List, Laboratoire National Henri Becquerel (LNE-LNHB), Palaiseau, France
| | | | - Stéphane Dufreneix
- Université Paris-Saclay, CEA, List, Laboratoire National Henri Becquerel (LNE-LNHB), Palaiseau, France; Institut de Cancérologie de l'Ouest, Angers, France
| | - Valentin Blideanu
- Université Paris-Saclay, CEA, List, Laboratoire National Henri Becquerel (LNE-LNHB), Palaiseau, France
| |
Collapse
|
5
|
Tarantino N, Litvinova E, Samri A, Soulié C, Morin V, Rousseau A, Dorgham K, Parizot C, Bonduelle O, Beurton A, Miyara M, Ghillani P, Mayaux J, Lhote R, Lacorte JM, Marcelin AG, Amoura Z, Luyt CE, Gorochov G, Guihot A, Vieillard V. Identification of natural killer markers associated with fatal outcome in COVID-19 patients. Front Cell Infect Microbiol 2023; 13:1165756. [PMID: 37342247 PMCID: PMC10277643 DOI: 10.3389/fcimb.2023.1165756] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Accepted: 05/18/2023] [Indexed: 06/22/2023] Open
Abstract
Introduction Increasing evidence has shown that coronavirus disease 19 (COVID-19) severity is driven by a dysregulated immunological response. Previous studies have demonstrated that natural killer (NK) cell dysfunction underpins severe illness in COVID-19 patients, but have lacked an in-depth analysis of NK cell markers as a driver of death in the most critically ill patients. Methods We enrolled 50 non-vaccinated hospitalized patients infected with the initial virus or the alpha variant of SARS-CoV-2 with moderate or severe illness, to evaluate phenotypic and functional features of NK cells. Results Here, we show that, consistent with previous studies, evolution NK cells from COVID-19 patients are more activated, with the decreased activation of natural cytotoxicity receptors and impaired cytotoxicity and IFN-γ production, in association with disease regardless of the SARS-CoV-2 strain. Fatality was observed in 6 of 17 patients with severe disease; NK cells from all of these patients displayed a peculiar phenotype of an activated memory-like phenotype associated with massive TNF-α production. Discussion These data suggest that fatal COVID-19 infection is driven by an uncoordinated inflammatory response in part mediated by a specific subset of activated NK cells.
Collapse
Affiliation(s)
- Nadine Tarantino
- Sorbonne Université, Inserm, CNRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Elena Litvinova
- Sorbonne Université, Inserm, CNRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département d’Immunologie, Paris, France
| | - Assia Samri
- Sorbonne Université, Inserm, CNRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Cathia Soulié
- Sorbonne Université, Inserm, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Laboratoire de Virologie, Paris, France
| | - Véronique Morin
- Sorbonne Université, Inserm, CNRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Alice Rousseau
- Sorbonne Université, Inserm, CNRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Karim Dorgham
- Sorbonne Université, Inserm, CNRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Christophe Parizot
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département d’Immunologie, Paris, France
| | - Olivia Bonduelle
- Sorbonne Université, Inserm, CNRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Alexandra Beurton
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Service de Médecine Intensive-Réanimation et Pneumologie, Paris, France
- Sorbonne Université, Inserm UMRS Neurophysiologie Respiratoire Expérimentale et Clinique, Assistance Publique – Hôpitaux de Paris (AP-HP), Paris, France
| | - Makoto Miyara
- Sorbonne Université, Inserm, CNRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département d’Immunologie, Paris, France
| | - Pascale Ghillani
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département d’Immunologie, Paris, France
| | - Julien Mayaux
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Service de Médecine Intensive-Réanimation et Pneumologie, Paris, France
| | - Raphael Lhote
- Service de Médecine Interne 2, Institut E3M, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Jean-Marc Lacorte
- Sorbonne Université, Inserm, UMRS1166-ICAN Institute of Cardiometabolism and Nutrition, Paris, France
- Service de Biochimie Endocrinienne et Oncologique, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Anne-Geneviève Marcelin
- Sorbonne Université, Inserm, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Laboratoire de Virologie, Paris, France
| | - Zahir Amoura
- Sorbonne Université, Inserm, CNRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
- Service de Médecine Interne 2, Institut E3M, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Charles-Edouard Luyt
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Service de Médecine Intensive-Réanimation et Pneumologie, Paris, France
- Service de Médecine Interne 2, Institut E3M, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, France
| | - Guy Gorochov
- Sorbonne Université, Inserm, CNRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département d’Immunologie, Paris, France
| | - Amélie Guihot
- Sorbonne Université, Inserm, CNRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département d’Immunologie, Paris, France
| | - Vincent Vieillard
- Sorbonne Université, Inserm, CNRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| |
Collapse
|
6
|
Stien C, Rousseau A, Bordy JM, Gouriou J. Preliminary dosimetric characterization of EDBreast gel. Biomed Phys Eng Express 2023. [PMID: 37236157 DOI: 10.1088/2057-1976/acd942] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
PURPOSE EDBreast gel is an alternative Fricke gel dosimeter, read by Magnetic Resonance Imaging, in which sucrose is added to lower diffusion effects. This paper aims at determining the dosimetric characteristics of this dosimeter.
Methods: The characterization has been performed in high energy photon beams. The dose-response of the gel has been evaluated as well as its detection limit, its fading effects, the reproducibility of its response and its stability over time. Its energy and dose-rate dependence has been investigated, and the overall dose uncertainty budget established. Once characterized, the dosimetry method has been applied to a simple reference irradiation case in a 6 MV photon beam, with the measurement of the lateral dose profile of a 2 x 2 cm² field. The results have been compared with microDiamond measurements.
Results: In addition to its low diffusivity, the gel presents a high sensitivity, no dose-rate dependence considering TPR(20-10) values ranging from 0.66 to 0.79 and an energy response comparable to ionization chambers. However, its non-linear dose-response induces a high uncertainty on the measured dose (8 % (k=1) at 20 Gy) and reproducibility issues. The profile measurements displayed discrepancies compared to the microDiamond due to diffusion effects. The appropriate spatial resolution was estimated using the diffusion coefficient. 
Conclusion: EDBreast gel dosimeter presents interesting characteristics for applications in clinics, but the linearity of its dose-response should be improved to lower the uncertainties and to enhance the reproducibility.
.
Collapse
Affiliation(s)
- Christel Stien
- DRT/LIST/DM2I/LNHB/LMD, Commissariat à l'énergie atomique et aux énergies alternatives Centre de Saclay, Centre Paris-Saclay, Bat 135 DOSEO, Gif-sur-Yvette, Ile-de-France, 91191, FRANCE
| | - Alice Rousseau
- DRT/LIST/DM2I/LNHB/LMD, Commissariat à l'énergie atomique et aux énergies alternatives Centre de Saclay, Centre Paris-Saclay, Bat 135 DOSEO, Gif-sur-Yvette, Ile-de-France, 91191, FRANCE
| | - Jean-Marc Bordy
- DRT/LIST/DETECS/LNHB/LMD, CEA - Saclay, F - 91191 Gif-Sur-Yvette Cedex, gif sur yvette, 91191, FRANCE
| | - Jean Gouriou
- Laboratoire National Henri Becquerel - BNM, CEA-CENS, CEA Saclay 91191, Gif-sur-Yvette, France, GIF-SUR-YVETTE, 91191, FRANCE
| |
Collapse
|
7
|
Rousseau A, Parisi C, Barlesi F. Anti-TIGIT therapies for solid tumors: a systematic review. ESMO Open 2023; 8:101184. [PMID: 36933320 PMCID: PMC10030909 DOI: 10.1016/j.esmoop.2023.101184] [Citation(s) in RCA: 21] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Revised: 01/26/2023] [Accepted: 02/12/2023] [Indexed: 03/18/2023] Open
Abstract
Programmed death-ligand 1[PD-(L)1], cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent breakthroughs in cancer treatment, however not all patients benefit from it. Thus new therapies are under investigation, such as anti-TIGIT [anti-T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif domains] antibodies. TIGIT is an immune checkpoint inhibiting lymphocyte T cells by several mechanisms. In vitro models showed its inhibition could restore antitumor response. Furthermore, its association with anti-PD-(L)1 therapies could synergistically improve survival. We carried out a review of the clinical trial about TIGIT referenced in the PubMed database, finding three published clinical trials on anti-TIGIT therapies. Vibostolimab was evaluated in a phase I alone or in combination with pembrolizumab. The combination had an objective response rate of 26% in patients with a non-small-cell lung cancer (NSCLC) naïve of anti-programmed cell death protein 1 (anti-PD-1). Etigilimab was tested in a phase I alone or in combination with nivolumab, but the study was stopped due to business reasons. In the phase II CITYSCAPE trial, tiragolumab demonstrated higher objective response rate and progression-free survival in combination with atezolizumab than atezolizumab alone in advanced PD-L1-high NSCLC. The ClinicalTrials.gov database references 70 trials of anti-TIGIT in patients with cancer, 47 of them with ongoing recruitment. Only seven were phase III, including five about patients with NSCLC, mostly with combination therapy. Data from phase I-II trials highlighted that targeting TIGIT represents a safe therapeutic approach, with an acceptable toxicity profile maintained when adding anti-PD-(L)1 antibodies. Frequent adverse events were pruritus, rash, and fatigue. Grade 3-4 adverse events were reported in nearly one in three patients. Anti-TIGIT antibodies are under development as a novel immunotherapy approach. A promising research area includes the combination with anti-PD-1 therapies in advanced NSCLCs.
Collapse
Affiliation(s)
- A Rousseau
- Medical Oncology Department, Gustave Roussy, Villejuif, France
| | - C Parisi
- Medical Oncology Department, Gustave Roussy, Villejuif, France
| | - F Barlesi
- Medical Oncology Department, Gustave Roussy, Villejuif, France; Faculté de Médecine, Université Paris-Saclay, Kremlin-Bicêtre, France.
| |
Collapse
|
8
|
Cambon-Binder A, Jaisson S, Tuffet S, Courties A, Eymard F, Okwieka A, Gillery P, Miquel A, Rousseau A, Crema MD, Berenbaum F, Sellam J. Serum carboxymethyllysine concentration is associated with erosive hand osteoarthritis. Osteoarthritis Cartilage 2023:S1063-4584(23)00727-6. [PMID: 36931384 DOI: 10.1016/j.joca.2023.03.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Revised: 01/30/2023] [Accepted: 03/03/2023] [Indexed: 03/19/2023]
Abstract
OBJECTIVE Carboxymethyllysine (CML) and homocitrulline (HCit) are the products of two non-enzymatic post-translational modifications of protein, a process related to age. We investigated whether serum CML and HCit concentrations were associated with hand osteoarthritis (HOA), especially erosive HOA. DESIGN Serum CML and HCit were measured by using liquid chromatography coupled with tandem mass spectrometry at inclusion in 386 patients included in the DIGICOD cohort. We investigated whether serum CML and/or HCit concentrations were associated with erosive HOA or with HOA clinical and radiological features. Moreover, we compared the tissular concentrations of CML and HCit in OA and non-OA cartilage from proximal interphalangeal and metacarpo-phalangeal (MCP) joints from human cadaveric donors. RESULTS Median (IQR) serum CML concentration was lower in patients with erosive HOA than those with non-erosive HOA (178.7 [157.1-208.8] vs 194.7 [168.9-217.1] μmol/mol Lys, p=0.002), but median HCit concentration did not differ between the groups (193.9 [162.9-232.0] vs 193.9 [155.9-224.6] μmol/mol Lys). Cartilage HCit and CML concentrations were not correlated with clinical features. Serum CML concentration was higher in OA than non-OA MCPs (7.0 vs 4.0 mmol/mol Lys, p=0.01). CONCLUSIONS Serum CML concentration was lower in erosive HOA than non-erosive HOA, and cartilage CML concentration was higher in OA than non-OA cartilage. These results encourage further studies to test whether serum CML could be a new prognostic biomarker in HOA.
Collapse
Affiliation(s)
- A Cambon-Binder
- Sorbonne University, Assistance Publique-Hôpitaux de Paris (AP-HP), Orthopaedic and Upper Limb Surgery Department, Saint-Antoine Hospital, Paris, France; Centre de Recherche Saint-Antoine, INSERM UMRS_938, Paris, France
| | - S Jaisson
- MEDyC Unit CNRS UMR n° 7369, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France; Biochemistry Department, University Hospital of Reims, Reims, France
| | - S Tuffet
- Sorbonne University, AP-HP, Service de Pharmacologie Clinique et Plateforme de Recherche Clinique de l'Est Parisien (URCEST, CRB, CRC), Saint-Antoine Hospital, Paris, France
| | - A Courties
- Centre de Recherche Saint-Antoine, INSERM UMRS_938, Paris, France; Sorbonne University, AP-HP, Rheumatology department, Saint-Antoine Hospital, Paris, France
| | - F Eymard
- Department of Rheumatology, AP-HP, Henri Mondor Hospital, 94000 Créteil, France
| | - A Okwieka
- MEDyC Unit CNRS UMR n° 7369, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France; Biochemistry Department, University Hospital of Reims, Reims, France
| | - P Gillery
- MEDyC Unit CNRS UMR n° 7369, Faculty of Medicine, University of Reims Champagne-Ardenne, Reims, France; Biochemistry Department, University Hospital of Reims, Reims, France
| | - A Miquel
- Sorbonne University, AP-HP, Radiology Department, Saint-Antoine Hospital, Paris, France
| | - A Rousseau
- Sorbonne University, AP-HP, Service de Pharmacologie Clinique et Plateforme de Recherche Clinique de l'Est Parisien (URCEST, CRB, CRC), Saint-Antoine Hospital, Paris, France
| | - M D Crema
- Institut d'Imagerie du Sport, Institut National du Sport, de l'Expertise et de la Performance (INSEP), Paris, France
| | - F Berenbaum
- Centre de Recherche Saint-Antoine, INSERM UMRS_938, Paris, France; Sorbonne University, AP-HP, Rheumatology department, Saint-Antoine Hospital, Paris, France
| | - J Sellam
- Centre de Recherche Saint-Antoine, INSERM UMRS_938, Paris, France; Sorbonne University, AP-HP, Rheumatology department, Saint-Antoine Hospital, Paris, France.
| |
Collapse
|
9
|
Rousseau A, Dubel-Jam M, Schantz C, Gaucher L. Barrier measures implemented in French maternity hospitals during the COVID-19 pandemic: A cross-sectional survey. Midwifery 2023; 118:103600. [PMID: 36680960 PMCID: PMC9839455 DOI: 10.1016/j.midw.2023.103600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 12/12/2022] [Accepted: 01/11/2023] [Indexed: 01/15/2023]
Abstract
OBJECTIVES The objectives of this survey were 1) to describe the changes over time of barrier measures in maternity units, specifically, co-parent visits and women wearing masks in birth rooms, and 2) to identify potential institutional determinants of these barrier measures. DESIGN We used an online questionnaire to conduct a descriptive cross-sectional survey from May to July 2021. SETTING All districts in mainland France. PARTICIPANTS Midwife supervisor of each maternity unit. MEASUREMENTS Primary outcomes were "banning of visits" in the postnatal department during the first lockdown (March-May 2020), and "mandated mask-wearing in birth rooms" during the survey period (May-July 2021); the independent variables were maternity unit characteristics and location in a crisis area. Co-parent visits were considered only during the first lockdown as they were mostly allowed afterwards, and the wearing of masks was studied only during the survey period, as masks were unavailable for the population during the first lockdown. RESULTS We obtained 343 responses, i.e., 75.2% of French maternity units. Visits to the postnatal department were forbidden in 39.3% of the maternity units during the first lockdown and in none during the study period. Maternity hospitals with neonatal intensive care units were the most likely to ban co-parent hospital visits (adjusted OR 2.34 [1.12; 4.96]). However, those were the maternity units least likely to encourage or require women to wear masks while pushing (adjusted OR, 0.31; 95% confidence interval [CI], 0.11-0.77). Maternity units in crisis areas (i.e., with very high case counts) during the first lockdown banned visits significantly more often (adjusted OR, 1.68; 95% CI, 1.05-2.70). KEY CONCLUSIONS Our study showed that barrier measures evolved during the course of the pandemic but remained extremely variable between facilities. IMPLICATIONS FOR PRACTICE Maternity units implemented drastic barrier measures at the beginning of the pandemic but were able to adapt these measures over time. It is now time to learn from this experience to ensure that women and infants are no longer harmed by these measures.
Collapse
Affiliation(s)
- A. Rousseau
- Midwifery Department, EA 7285, Versailles Saint Quentin University, F-78180 Montigny-le-Bretonneux, France,Department of Obstetrics and Gynecology, Poissy-Saint Germain Hospital, F-78300 Poissy, France,Université Paris-Saclay, UVSQ, Inserm, Équipe Epidémiologie clinique, CESP, 78180 Montigny le Bretonneux, France,Corresponding author at: UFR Simone Veil-Santé - 2 avenue de la Source de la Bièvre, F-78180 Montigny-le-Bretonneux, France
| | - M. Dubel-Jam
- Midwifery Department, EA 7285, Versailles Saint Quentin University, F-78180 Montigny-le-Bretonneux, France,Department of Obstetrics and Gynecology, Poissy-Saint Germain Hospital, F-78300 Poissy, France
| | - C. Schantz
- Université Paris Cité, IRD, Inserm, Ceped, F-75006 Paris, France
| | - L. Gaucher
- Geneva School of Health Sciences, HES-SO University of Applied Sciences and Arts, Western Switzerland, Geneva, Switzerland,Université Claude Bernard Lyon 1, Research on Healthcare Performance (RESHAPE), INSERM U1290, F-69008 Lyon, France,Hospices Civils de Lyon, Hôpital Femme Mère-Enfant, F-69500 Bron, France
| |
Collapse
|
10
|
Hernández-Verdin I, Kirasic E, Wienand K, Mokhtari K, Eimer S, Loiseau H, Rousseau A, Paillassa J, Ahle G, Lerintiu F, Uro-Coste E, Oberic L, Figarella-Branger D, Chinot O, Gauchotte G, Taillandier L, Marolleau JP, Polivka M, Adam C, Ursu R, Schmitt A, Barillot N, Nichelli L, Lozano-Sánchez F, Ibañez-Juliá MJ, Peyre M, Mathon B, Abada Y, Charlotte F, Davi F, Stewart C, de Reyniès A, Choquet S, Soussain C, Houillier C, Chapuy B, Hoang-Xuan K, Alentorn A. Molecular and clinical diversity in primary central nervous system lymphoma. Ann Oncol 2023; 34:186-199. [PMID: 36402300 DOI: 10.1016/j.annonc.2022.11.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Accepted: 11/08/2022] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Primary central nervous system lymphoma (PCNSL) is a rare and distinct entity within diffuse large B-cell lymphoma presenting with variable response rates probably to underlying molecular heterogeneity. PATIENTS AND METHODS To identify and characterize PCNSL heterogeneity and facilitate clinical translation, we carried out a comprehensive multi-omic analysis [whole-exome sequencing, RNA sequencing (RNA-seq), methylation sequencing, and clinical features] in a discovery cohort of 147 fresh-frozen (FF) immunocompetent PCNSLs and a validation cohort of formalin-fixed, paraffin-embedded (FFPE) 93 PCNSLs with RNA-seq and clinico-radiological data. RESULTS Consensus clustering of multi-omic data uncovered concordant classification of four robust, non-overlapping, prognostically significant clusters (CS). The CS1 and CS2 groups presented an immune-cold hypermethylated profile but a distinct clinical behavior. The 'immune-hot' CS4 group, enriched with mutations increasing the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) and nuclear factor-κB activity, had the most favorable clinical outcome, while the heterogeneous-immune CS3 group had the worse prognosis probably due to its association with meningeal infiltration and enriched HIST1H1E mutations. CS1 was characterized by high Polycomb repressive complex 2 activity and CDKN2A/B loss leading to higher proliferation activity. Integrated analysis on proposed targets suggests potential use of immune checkpoint inhibitors/JAK1 inhibitors for CS4, cyclin D-Cdk4,6 plus phosphoinositide 3-kinase (PI3K) inhibitors for CS1, lenalidomide/demethylating drugs for CS2, and enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) inhibitors for CS3. We developed an algorithm to identify the PCNSL subtypes using RNA-seq data from either FFPE or FF tissue. CONCLUSIONS The integration of genome-wide data from multi-omic data revealed four molecular patterns in PCNSL with a distinctive prognostic impact that provides a basis for future clinical stratification and subtype-based targeted interventions.
Collapse
Affiliation(s)
- I Hernández-Verdin
- Institut du Cerveau-Paris Brain Institute-ICM, Inserm, Sorbonne Université, CNRS, Paris, France
| | - E Kirasic
- Institut du Cerveau-Paris Brain Institute-ICM, Inserm, Sorbonne Université, CNRS, Paris, France
| | - K Wienand
- Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Berlin, Germany; Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - K Mokhtari
- Institut du Cerveau-Paris Brain Institute-ICM, Inserm, Sorbonne Université, CNRS, Paris, France; Department of Neuropathology, Groupe Hospitalier Pitié Salpêtrière, APHP, Paris, France
| | - S Eimer
- Department of Pathology, CHU de Bordeaux, Hôpital Pellegrin, Bordeaux, France
| | - H Loiseau
- Department of Neurosurgery, Bordeaux University Hospital Center, Pellegrin Hospital, Bordeaux, France; EA 7435-IMOTION, University of Bordeaux, Bordeaux, France
| | - A Rousseau
- Department of Pathology, PBH, CHU Angers, Angers, France; CRCINA, Université de Nantes-université d'Angers, Angers, France
| | - J Paillassa
- Department of Hematology, CHU Angers, Angers, France
| | - G Ahle
- Department of Neurology, Hôpitaux Civils de Colmar, Colmar, France
| | - F Lerintiu
- Department of Neuropathology, Hôpitaux Civils de Colmar, Strasbourg, France
| | - E Uro-Coste
- Department of Pathology, CHU de Toulouse, IUC-Oncopole, Toulouse, France; INSERM U1037, Cancer Research Center of Toulouse (CRCT), Toulouse, France; Université Toulouse III Paul Sabatier, Toulouse, France
| | - L Oberic
- Department of Hematology, IUC Toulouse Oncopole, Toulouse, France
| | - D Figarella-Branger
- Neuropathology Department, University Hospital Timone, Aix Marseille University, Marseille, France; Inst Neurophysiopathol, CNRS, INP, Aix-Marseille University, Marseille, France
| | - O Chinot
- Department of Neuro-oncology, CHU Timone, APHM, Marseille, France; Institute of NeuroPhysiopathology, CNRS, INP, Aix-Marseille University, Marseille, France
| | - G Gauchotte
- Department of Biopathology, CHRU Nancy, CHRU/ICL, Bâtiment BBB, Vandoeuvre-lès-Nancy, France; Department of Legal Medicine, CHRU Nancy, Vandoeuvre-lès-Nancy, France; INSERM U1256, University of Lorraine, Vandoeuvre-lès-Nancy, France; Centre de Ressources Biologiques, BB-0033-00035, CHRU, Nancy, France
| | - L Taillandier
- Department of Neuro-oncology, CHRU-Nancy, Université de Lorraine, Nancy, France
| | - J-P Marolleau
- Department of Hematology, CHU Amiens-Picardie, Amiens, France
| | - M Polivka
- Department of Anatomopathology, Lariboisière Hospital, Assistance Publique-Hopitaux de Paris, University of Paris, Paris, France
| | - C Adam
- Pathology Department, Bicêtre University Hospital, Public Hospital Network of Paris, Le Kremlin Bicêtre, France
| | - R Ursu
- Department of Neurology, Université de Paris, AP-HP, Hôpital Saint Louis, Paris, France
| | - A Schmitt
- Department of Hematology, Institut Bergonié Hospital, Bordeaux, France
| | - N Barillot
- Institut du Cerveau-Paris Brain Institute-ICM, Inserm, Sorbonne Université, CNRS, Paris, France
| | - L Nichelli
- Department of Neuroradiology, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, Paris, France
| | - F Lozano-Sánchez
- Department of Neurology-2, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, Paris, France
| | | | - M Peyre
- Institut du Cerveau-Paris Brain Institute-ICM, Inserm, Sorbonne Université, CNRS, Paris, France; Department of Neurosurgery, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, Paris, France
| | - B Mathon
- Institut du Cerveau-Paris Brain Institute-ICM, Inserm, Sorbonne Université, CNRS, Paris, France; Department of Neurosurgery, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, Paris, France
| | - Y Abada
- Department of Neurology-2, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, Paris, France
| | - F Charlotte
- Department Pathology, Hôpital Pitié-Salpêtrière and Sorbonne University, Paris, France
| | - F Davi
- Department Hematology, APHP, Hôpital Pitié-Salpêtrière and Sorbonne University, Paris, France
| | - C Stewart
- Department Broad Institute of MIT and Harvard, Cambridge, USA
| | - A de Reyniès
- Department INSERM UMR_S1138-Centre de Recherche des Cordeliers-Université Pierre et Marie Curie et Université Paris Descartes, Paris, France
| | - S Choquet
- Department Pathology, Hôpital Pitié-Salpêtrière and Sorbonne University, Paris, France
| | - C Soussain
- Department Hematology Unit, Institut Curie, Saint-Cloud, France
| | - C Houillier
- Department of Neurology-2, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, Paris, France
| | - B Chapuy
- Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - K Hoang-Xuan
- Institut du Cerveau-Paris Brain Institute-ICM, Inserm, Sorbonne Université, CNRS, Paris, France; Department of Neurology-2, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, Paris, France
| | - A Alentorn
- Institut du Cerveau-Paris Brain Institute-ICM, Inserm, Sorbonne Université, CNRS, Paris, France; Department of Neurology-2, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière-Charles Foix, Paris, France.
| |
Collapse
|
11
|
Rousseau A, Vauloup-Fellous C, Haigh O, Pavy S, Molinari D, Jauréguiberry S, Angoulvant A, Labetoulle M. Conjunctival conveyance of SARS-CoV-2 in asymptomatic and non-severe symptomatic COVID-19 patients. J Fr Ophtalmol 2023; 46:101-105. [PMID: 36635207 PMCID: PMC9812824 DOI: 10.1016/j.jfo.2022.09.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Accepted: 09/13/2022] [Indexed: 01/07/2023]
Abstract
INTRODUCTION The prevalence of ocular conveyance of SARS-CoV-2 has been well described for severe/hospitalized cases, but scarcely reported in asymptomatic and non-severe patients, who are unaware that they are carriers. MATERIAL & METHODS This prospective cross-sectional study quantitatively evaluated SARS-CoV-2 shedding on the ocular surface (OS). Conjunctival testing was suggested to all hospital personnel being screened by nasopharyngeal (NP) SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR). Disease symptoms were evaluated using a standardized questionnaire and telephone follow-up 6±3 months later for disease evolution (recovery with/without severe disease). RESULTS Four hundred and eighty seven patients were included. From 46 NP SARS-CoV-2-positive subjects (cycle threshold [CT]=24.2±7.1), 13% tested positive at the OS (CT=36.4±2.8). Most SARS-CoV-2-positive subjects were symptomatic (n=40, 87%), while 6 were asymptomatic (being tested as contact cases). Systemic symptoms were not significantly different in OS-positive vs OS-negative subjects, although headache tended to be more frequent in OS-positives (83% vs 54%, P=0.06). None of the OS-positive subjects reported ocular symptoms and none developed severe disease requiring hospitalization or oxygen therapy. CONCLUSION SARS-CoV-2 shedding at the OS may occur in asymptomatic and non-severe COVID-19 individuals (including those absent of ocular symptoms). However, the high RT-PCR CT values attained may indicate a low risk of transmissibility via this route.
Collapse
Affiliation(s)
- A Rousseau
- Department of Ophthalmology, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, French Reference network for rare Ophthalmologic diseases (OPHTARA), Le Kremlin-Bicêtre, France; Immunology of viral and autoimmune disease, IMVA, IDMIT, U1184, CEA, Fontenay aux Roses, France
| | - C Vauloup-Fellous
- Division of Virology, Dept of Biology Genetics and PUI, Paris-Saclay University Hospital, APHP, Villejuif, France; Inserm U1193, Université Paris-Saclay, Villejuif, France
| | - O Haigh
- Immunology of viral and autoimmune disease, IMVA, IDMIT, U1184, CEA, Fontenay aux Roses, France
| | - S Pavy
- Department of Rheumatology, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, Le Kremlin-Bicêtre, France
| | - D Molinari
- Clinical Research Unit, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, Le Kremlin-Bicêtre, France
| | - S Jauréguiberry
- Department of Infectious and tropical diseases, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, Le Kremlin-Bicêtre, France; Université de Paris Saclay, INSERM, CESP (Centre de Recherche en Epidémiologie et Santé des Populations), Villejuif, France
| | - A Angoulvant
- Department of Infectious and tropical diseases, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, Le Kremlin-Bicêtre, France; QE-Le Moulon, INRA-Université Paris-Saclay-CNRS-AgroParisTech, 91400 Orsay, France
| | - M Labetoulle
- Department of Ophthalmology, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Paris-Saclay University, French Reference network for rare Ophthalmologic diseases (OPHTARA), Le Kremlin-Bicêtre, France; Immunology of viral and autoimmune disease, IMVA, IDMIT, U1184, CEA, Fontenay aux Roses, France
| |
Collapse
|
12
|
Hoarau G, Vauloup Fellous C, Haigh O, Labetoulle M, Rousseau A. [Monkeypox: Important facts for the ophthalmologist]. J Fr Ophtalmol 2023; 46:185-193. [PMID: 36639339 PMCID: PMC9832348 DOI: 10.1016/j.jfo.2022.11.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2022] [Revised: 11/11/2022] [Accepted: 11/14/2022] [Indexed: 01/13/2023]
Abstract
The current monkeypox virus (MPXV) outbreak, raging since May 2022, is the largest ever observed on a world-wide scale. Despite previously being endemic in west and central Africa with a mortality rate of up to 10%, it remained a neglected tropical disease. Along with other recent pandemics gaining much attention, this MPXV outbreak has provided an opportunity to improve our understanding of its physiopathology and better define management strategies, particularly in patients with more serious disease. From the ophthalmologist's perspective, eyelid involvement and conjunctivitis or keratoconjunctivitis are frequently observed and may precede systemic signs or even remain the major site of involvement. While the course of MPXV keratoconjunctivitis is most often favorable, severe cases pose a functional threat, in particular for immunocompromised patients. This review provides an overview of MPXV pathophysiology, diagnosis and treatment, as well as considerations for prevention of transmission. During such an epidemic, the ophthalmologist can be the first to diagnose MPXV, treat the ocular involvement, and set up adequate preventative measures in collaboration with infectious disease specialists.
Collapse
Affiliation(s)
- G. Hoarau
- Service d’ophtalmologie, réseau OPHTARA, CHU Bicêtre Paris-Saclay, université Paris Saclay, AP–HP, Kremlin-Bicêtre, France
| | - C. Vauloup Fellous
- Service de virologie, HU Paul Brousse Paris Saclay, université Paris Saclay, AP–HP, Villejuif, France,Département d’immunologie des maladies virales, auto-immunes, hématologiques et bactériennes, UMR1184, CEA Fontenay-Aux-Roses, France
| | - O. Haigh
- Département d’immunologie des maladies virales, auto-immunes, hématologiques et bactériennes, UMR1184, CEA Fontenay-Aux-Roses, France
| | - M. Labetoulle
- Service d’ophtalmologie, réseau OPHTARA, CHU Bicêtre Paris-Saclay, université Paris Saclay, AP–HP, Kremlin-Bicêtre, France,Département d’immunologie des maladies virales, auto-immunes, hématologiques et bactériennes, UMR1184, CEA Fontenay-Aux-Roses, France
| | - A. Rousseau
- Service d’ophtalmologie, réseau OPHTARA, CHU Bicêtre Paris-Saclay, université Paris Saclay, AP–HP, Kremlin-Bicêtre, France,Département d’immunologie des maladies virales, auto-immunes, hématologiques et bactériennes, UMR1184, CEA Fontenay-Aux-Roses, France,Auteur correspondant. Service d’ophtalmologie, CHU Bicêtre, 78, rue du Général Leclerc, 94275 Le Kremlin-Bicêtre, France
| |
Collapse
|
13
|
Entenberg GA, Dosovitsky G, Aghakhani S, Mostovoy K, Carre N, Marshall Z, Benfica D, Mizrahi S, Testerman A, Rousseau A, Lin G, Bunge EL. User experience with a parenting chatbot micro intervention. Front Digit Health 2023; 4:989022. [PMID: 36714612 PMCID: PMC9874295 DOI: 10.3389/fdgth.2022.989022] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2022] [Accepted: 12/20/2022] [Indexed: 01/12/2023] Open
Abstract
Background The use of chatbots to address mental health conditions have become increasingly popular in recent years. However, few studies aimed to teach parenting skills through chatbots, and there are no reports on parental user experience. Aim: This study aimed to assess the user experience of a parenting chatbot micro intervention to teach how to praise children in a Spanish-speaking country. Methods A sample of 89 parents were assigned to the chatbot micro intervention as part of a randomized controlled trial study. Completion rates, engagement, satisfaction, net promoter score, and acceptability were analyzed. Results 66.3% of the participants completed the intervention. Participants exchanged an average of 49.8 messages (SD = 1.53), provided an average satisfaction score of 4.19 (SD = .79), and reported that they would recommend the chatbot to other parents (net promoter score = 4.63/5; SD = .66). Acceptability level was high (ease of use = 4.66 [SD = .73]; comfortability = 4.76 [SD = .46]; lack of technical problems = 4.69 [SD = .59]; interactivity = 4.51 [SD = .77]; usefulness for everyday life = 4.75 [SD = .54]). Conclusions Overall, users completed the intervention at a high rate, engaged with the chatbot, were satisfied, would recommend it to others, and reported a high level of acceptability. Chatbots have the potential to teach parenting skills however research on the efficacy of parenting chatbot interventions is needed.
Collapse
Affiliation(s)
- G. A. Entenberg
- Research Department, Fundación ETCI, Buenos Aires, Argentina,Correspondence: G. A. Entenberg E. L. Bunge
| | - G. Dosovitsky
- Children and Adolescents Psychotherapy and Technology Lab (CAPT), Palo Alto University, Palo Alto, CA, United States
| | - S. Aghakhani
- Children and Adolescents Psychotherapy and Technology Lab (CAPT), Palo Alto University, Palo Alto, CA, United States
| | - K. Mostovoy
- Children and Adolescents Psychotherapy and Technology Lab (CAPT), Palo Alto University, Palo Alto, CA, United States
| | - N. Carre
- Children and Adolescents Psychotherapy and Technology Lab (CAPT), Palo Alto University, Palo Alto, CA, United States
| | - Z. Marshall
- Children and Adolescents Psychotherapy and Technology Lab (CAPT), Palo Alto University, Palo Alto, CA, United States
| | - D. Benfica
- Children and Adolescents Psychotherapy and Technology Lab (CAPT), Palo Alto University, Palo Alto, CA, United States
| | - S. Mizrahi
- Research Department, Fundación ETCI, Buenos Aires, Argentina
| | - A. Testerman
- Children and Adolescents Psychotherapy and Technology Lab (CAPT), Palo Alto University, Palo Alto, CA, United States
| | - A. Rousseau
- Children and Adolescents Psychotherapy and Technology Lab (CAPT), Palo Alto University, Palo Alto, CA, United States
| | - G. Lin
- Children and Adolescents Psychotherapy and Technology Lab (CAPT), Palo Alto University, Palo Alto, CA, United States
| | - E. L. Bunge
- Children and Adolescents Psychotherapy and Technology Lab (CAPT), Palo Alto University, Palo Alto, CA, United States,Department of Psychology, International Institute for Internet Interventions i4Health, Palo Alto, CA, United States,Correspondence: G. A. Entenberg E. L. Bunge
| |
Collapse
|
14
|
Chaudot F, Sève P, Rousseau A, Alexandre M, Fournie P, Lozac’h P, Keraen J, Servant M, Muller R, Gramont B, Touhami S, Mahmoud H, Quintart P, Dalle S, Lambotte O, Kodjikian L, Jamilloux Y. Inflammation oculaire induite par les inhibiteurs du checkpoint immunitaire. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
15
|
Voillequin S, Rozenberg P, Letutour K, Rousseau A. Comparative satisfaction and effectiveness of virtual simulation and usual supervised work for postpartum hemorrhage management: a crossover randomized controlled trial. BMC Med Educ 2022; 22:709. [PMID: 36203183 PMCID: PMC9540154 DOI: 10.1186/s12909-022-03761-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Accepted: 09/19/2022] [Indexed: 06/16/2023]
Abstract
BACKGROUND Because virtual simulation promotes learning and cognitive skill development, it may be useful for teaching students to manage postpartum hemorrhage (PPH) and its complex decision algorithm. OBJECTIVE This study aimed to compare the satisfaction and effectiveness of virtual simulation with usual supervised work in producing knowledge and satisfaction. METHODS This two-center two-stage crossover randomized controlled trial included student midwives. One group underwent the virtual simulation intervention in the first period (January 2018) and the usual supervised classroom work in the second (May 2018); the other group followed the reverse chronology. Satisfaction was the primary outcome. The secondary outcome was knowledge of the PPH management algorithm, assessed by responses to a case vignette after each intervention session. RESULTS The virtual simulation -supervised work (VS-SW) chronology was allocated to 48 students, and its inverse (SW-VS) to 47; Satisfaction was significantly higher for the virtual simulation for its overall grade (6.8 vs. 6.1, P = 0.009), engagingness (very good 82.1% vs. 24.3%, P < 0.001), and ease of use (very good 77.9% vs. 46.1%, P < 0.001). Knowledge did not differ between the two groups (respectively, 89.5% versus 83.5%, P = 0.3). CONCLUSION Satisfaction is higher with virtual simulation without lowering knowledge scores, which argues for the use of such innovative teaching strategies. This could lead to an increase in students' motivation to learn.
Collapse
Affiliation(s)
| | - P Rozenberg
- Department of Obstetrics and Gynecology, Poissy-Saint Germain Hospital, 78300, Poissy, France
- Clinical Epidemiology, Paris Saclay University, CESP, UVSQ, Inserm, Team U1018, 78180, Montigny- le-Bretonneux, France
| | - K Letutour
- Department of Obstetrics and Gynecology, Poissy-Saint Germain Hospital, 78300, Poissy, France
- Midwifery Department, UVSQ, 78180, Montigny-le-Bretonneux, France
| | - A Rousseau
- Department of Obstetrics and Gynecology, Poissy-Saint Germain Hospital, 78300, Poissy, France
- Clinical Epidemiology, Paris Saclay University, CESP, UVSQ, Inserm, Team U1018, 78180, Montigny- le-Bretonneux, France
- Midwifery Department, UVSQ, 78180, Montigny-le-Bretonneux, France
| |
Collapse
|
16
|
Meurisse PL, Eid L, Rousseau A. Dacryoadenitis in giant cell arteritis. J Fr Ophtalmol 2022; 45:829-830. [DOI: 10.1016/j.jfo.2021.11.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Accepted: 11/30/2021] [Indexed: 10/17/2022]
|
17
|
Faure P, Limam L, de Saint-Sauveur G, Da Cunha E, Best AL, Bénichou J, Remongin PE, Vauloup-Fellous C, Eid L, Labetoulle M, Rousseau A. Diagnostic virologique des atteintes oculaires herpétiques antérieures sur prélèvement lacrymal : une technique simple et non invasive. J Fr Ophtalmol 2022; 45:735-740. [DOI: 10.1016/j.jfo.2022.03.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 03/28/2022] [Accepted: 03/29/2022] [Indexed: 11/25/2022]
|
18
|
Carbonnel M, Daclin C, Tarantino N, Groiseau O, Morin V, Rousseau A, Vasse M, Hertig A, Kennel T, Ayoubi JM, Vieillard V. Plasticity of natural killer cells in pregnant patients infected with SARS-CoV-2 and their neonates during childbirth. Front Immunol 2022; 13:893450. [PMID: 35911747 PMCID: PMC9335005 DOI: 10.3389/fimmu.2022.893450] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2022] [Accepted: 06/28/2022] [Indexed: 12/03/2022] Open
Abstract
The COVID-19 pandemic has occurred due to infection caused by the SARS-CoV-2 coronavirus, which impacts gestation and pregnancy. In SARS-CoV-2 infection, only very rare cases of vertical transmission have been reported, suggesting that fetal immune imprinting due to a maternal infection is probably a result of changes in maternal immunity. Natural killer (NK) cells are the leading maternal immune cells that act as a natural defense system to fight infections. They also play a pivotal role in the establishment and maintenance of pregnancy. While peripheral NK cells display specific features in patients infected with SARS-CoV-2 in the general population, information remains elusive in pregnant mothers and neonates. In the present study, we analyzed the characteristics of NK cells isolated from both neonatal umbilical cord blood and maternal peripheral blood close to the time of delivery. Phenotype and functions were compared in 18 healthy pregnant women and 34 COVID-19 patients during pregnancy within an ongoing infection (PCR+; N = 15) or after recovery (IgG+PCR−; N = 19). The frequency of NK cells from infected women and their neonates was correlated with the production of inflammatory cytokines in the serum. The expression of NKG2A and NKp30, as well as degranulation of NK cells in pregnant women with ongoing infection, were both negatively correlated to estradiol level. Furthermore, NK cells from the neonates born to infected women were significantly decreased and also correlated to estradiol level. This study highlights the relationship between NK cells, inflammation, and estradiol in patients with ongoing infection, providing new insights into the impact of maternal SARS-CoV-2 infection on the neonate.
Collapse
Affiliation(s)
- Marie Carbonnel
- Department of Obstetrics and Gynecology, Hôpital Foch, Suresnes, France
- University of Versailles, Versailles, France
| | - Camille Daclin
- Department of Obstetrics and Gynecology, Hôpital Foch, Suresnes, France
- University of Versailles, Versailles, France
| | - Nadine Tarantino
- Sorbonne Université, Inserm U1135, CNRS ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Olivia Groiseau
- Sorbonne Université, Inserm U1135, CNRS ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Véronique Morin
- Sorbonne Université, Inserm U1135, CNRS ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Alice Rousseau
- Sorbonne Université, Inserm U1135, CNRS ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
| | - Marc Vasse
- Department of Clinical Biology, Hôpital Foch, Suresnes, France
- INSERM UMRS-1176, University Paris-Sud, Orsay, France
| | - Alexandre Hertig
- Nephrology and Renal Transplantation Department, Hôpital Foch, Suresnes, France
| | - Titouan Kennel
- Department of Clinic Research, Hôpital Foch, Suresnes, France
| | - Jean Marc Ayoubi
- Department of Obstetrics and Gynecology, Hôpital Foch, Suresnes, France
- University of Versailles, Versailles, France
| | - Vincent Vieillard
- Sorbonne Université, Inserm U1135, CNRS ERL 8255, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
- *Correspondence: Vincent Vieillard,
| |
Collapse
|
19
|
Tan E, Tuffet S, Rousseau A, Fautrel B, Rannou F, Berenbaum F, Sellam J, Courties A. POS1111 WHAT DOES GRIP STRENGTH REFLECT IN HAND OSTEOARTHRITIS? RESULTS FROM THE DIGICOD COHORT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundAmong the general population over 60 years-old, the decrease in grip strength is a marker of morbidity and mortality: its measurement during follow-up consultations is considered as a predictive marker of good health status or the patient’s overall fragility (1). However, hand osteoarthritis (HOA), which can modulate grip strength and is also associated with comorbidities is never taken into account, while it is a very common disease.ObjectivesThe objectives of this study are to describe grip strength in a symptomatic HOA population, to investigate painful osteoarthritic joints associated with decreased grip strength, and to determine whether decreased grip strength is independently associated with comorbidities in this population.MethodsDIGICOD is a hospital-based observational cohort including patients with radiographic features of HOA of at least 2 joints or radiographic thumb base OA. Inflammatory rheumatism or crystal arthropathy were excluded. The data at baseline were used for the analysis. Grip strength was the higher score of 3 repeated measures using a Jamar dynamometer. Baseline grip strength of the dominant hand was compared in the cohort between men and women (Student’s T test) and was described by age (by 10-year age groups using Kruskal-Wallis test). In this cross-sectional study, factors associated with a decreased grip strength were investigated using univariate and then multivariate linear regression analysis (with adjustment on age, BMI and variables with p ≤ 0.2 in univariate analysis) with stratification by sex. Results were presented by beta coefficients and their 95% confidence intervals. A first analysis focused on the association of grip strength with local factors: painful locations in the dominant hand by row and radiographic severity according to the total Kellgren-Lawrence (KL) score. The second analysis assessed the patient-level association between decreased grip strength and general characteristics, including cumulative comorbidities and markers of radio-clinical severity of hand OA, namely the AUSCAN pain score and total KL score. A sensitivity analysis was performed to look for association between grip strength and each comorbidity.Results394 patients were analyzed, including 329 women (mean ± SD of the dominant hand’s grip strength of 21.6 ± 6.9 kg) and 65 men (34.9 ± 9.8 kg) with a mean age of 66.9 ± 7.3 years. Grip strength decreased with age (p<0.001) and was lower for women (p<0.0001).Among women, locally, decreased grip strength was independently associated with painful involvement of at least 2 metacarpophalangeal joints (MCPs) (estimated coefficient [95% CI] -3.6 [-6.2; -1.0] kg versus no painful MCPs) but not with proximal and distal interphalangeal joints, and with a high KL total sum score (-0.06 [-0.10; -0.01] kg per additional point). At the patient-level, decreased grip strength was not associated with comorbidities but with radio-clinical severity (p<0.05), i.e. a higher KL total sum score and AUSCAN pain score.Among men, neither radiographic severity nor painful locations were independently associated with a decrease of grip strength. Conversely, decreased grip strength was associated with at least 3 comorbidities (-8.5 [-15.5; -1.43] kg versus a single comorbidity being OA), independently of radiographic severity. The study of comorbidities individually did not show any particular association with grip strength.ConclusionIn this cohort of symptomatic HOA, the decrease of grip strength reflects the radio-clinical severity of hand OA among women, whereas among men, it is independently associated with the accumulation of comorbidities. The presence of hand OA should be considered for further studies investigation the relationship between grip strength and morbi-mortality.References[1]Bohannon RW. Grip Strength: An Indispensable Biomarker For Older Adults. CIA. oct 2019;Volume 14:1681‑91.Graph 1.Grip strength according to the number of comorbidities among men and womenDisclosure of InterestsNone declared
Collapse
|
20
|
Duvillier C, Gams J, Rousseau A, Rozenberg P. [Induction of labour with oral misoprostol versus vaginal misoprostol: A before-after study]. Gynecol Obstet Fertil Senol 2022; 50:475-480. [PMID: 35151915 DOI: 10.1016/j.gofs.2022.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 01/28/2022] [Accepted: 01/31/2022] [Indexed: 06/14/2023]
Abstract
OBJECTIVE The rate of induction of labor represented 22 % of deliveries in 2016 in France. Oral misoprostol (Angusta®) was marketed in France in the last quarter of 2018. The objective of our study was to compare the efficacy and safety of induction of labor with oral misoprostol compared to vaginal misoprostol in women with an unripe cervix. MATERIAL AND METHODS We carried out a retrospective study before and after the implementation of oral misoprostol including all women with an unripe cervix who benefited from an induction of labor with a viable infant in vertex presentation, without uterine scar. During the first two-year period, women received 50μg of misoprostol in the posterior fornix, repeated 6hours later if needed. If labor had not started after 24hours, women received another dose of 50μg, which was repeated every 4hours until labor was established, up to a total dose of 150μg. During the second two-year period, women received two tablets of oral misoprostol 25μg every four hours if necessary, up to a total dose of 200μg. The primary endpoints were mode of delivery and neonatal safety. RESULTS During the two study periods, 1199 women received vaginal misoprostol and 1199 women received oral misoprostol including. The cesarean delivery rate was 21.8% during the first period and 21,3% during the second period (P=0.83). A 5-minutes Apgar score<7 was observed in 23 (1.9%) and 14 (1.2%) newborns in the vaginal misoprostol and oral misoprostol groups (P=0.14), respectively. An arterial cord pH<7.00 was observed in 6 (0.5%) and 7 (0.6%) newborns (P=0.99), respectively. CONCLUSION Oral misoprostol administered at the dose of 50μg every 4hours (up to a total dose of 200μg) is as effective and safe as the vaginal misoprostol to induce labor in women with an unripe cervix.
Collapse
Affiliation(s)
- C Duvillier
- Université Paris Saclay, UVSQ, Inserm, équipe U1018, épidémiologie clinique, CESP, 78180 Montigny-le-Bretonneux, France; Centre Hospitalier Poissy/Saint-germain, service d'obstétrique et gynécologie, 10, rue du Champ Gaillard, 78300 Poissy, France.
| | - J Gams
- Centre Hospitalier Poissy/Saint-germain, service d'obstétrique et gynécologie, 10, rue du Champ Gaillard, 78300 Poissy, France
| | - A Rousseau
- Université Paris Saclay, UVSQ, Inserm, équipe U1018, épidémiologie clinique, CESP, 78180 Montigny-le-Bretonneux, France
| | - P Rozenberg
- Université Paris Saclay, UVSQ, Inserm, équipe U1018, épidémiologie clinique, CESP, 78180 Montigny-le-Bretonneux, France; Centre Hospitalier Poissy/Saint-germain, service d'obstétrique et gynécologie, 10, rue du Champ Gaillard, 78300 Poissy, France; Réseau maternité en Yvelines et périnatalité Active (MYPA), 20, rue Armagis, Pavillon Courtois, 78100 Saint-Germain-en-Laye, France
| |
Collapse
|
21
|
Djossou HJ, Tuffet S, Rousseau A, Latourte A, Laredo JD, Berenbaum F, Sellam J. AB0967 IMPACT OF CARPAL TUNNEL SYNDROME ON SYMPTOMS AND STRUCTURAL SEVERITY OF HAND OSTEOARTHRITIS: RESULTS FROM THE DIGICOD COHORT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundCarpal tunnel syndrome (CTS) and hand osteoarthritis (HOA) are common diseases that can coexist in the same patient. Only one recent study showed that CTS was associated with a significant decrease in strength and performance of the OA-affected hand [1]. This observation suggested that CTS-induced neuropathic disorders may have effects on the surrounding joints symptomatically supporting the role of nerve-joint axis in OA pain.ObjectivesOur work aimed to study the impact of CTS on the symptoms and structural severity of HOA in the DIGICOD (DIGItal Cohort Design) cohort.MethodsDIGICOD is a single-center prospective hospital cohort which includes 426 patients over 35 years of age with symptomatic HOA [2]. Patients in our study were those in the DIGICOD cohort at inclusion for whom the dominant hand and laterality in case of CTS involvement were known. The analysis was based on the study of the dominant hand. We compared the demographic, clinical and radiographic characteristics (notably by the sum of the Kellgren Lawrence (KL) score) between patients with CTS and those without CTS. In case of comparison test, Chi-square or Fisher exact test were performed. Then, we investigated whether CTS was associated with grips strength, pinch strength and KL score by linear regression model and with number of joints painful pressure with negative-binomial model, after adjustment for age and sex.Results417 patients including 39 with CTS were included in our study. Obesity and metabolic syndrome were more frequent in patients with CTS than in those without CTS (obesity: 29.7% vs 10.2%, p<0.01; metabolic syndrome: 51.4% vs 35.1%, p<0.05). The same was true for dysthyroidism (38.5% vs 18.5%, p<0.01) and thyroid hormone replacement therapy (30.8% vs 15.4%, p<0.05). At the level of the dominant hand, clinical signs of HOA (painful, swollen, or nodal joints), sum of Kellgren Lawrence (KL) score, number of joints with a KL score ≥ 2, and the presence of erosive HOA (defined by the presence of at least 1 erosive joint defined as phase “E” or “R” in the Verbruggen scoring) were comparable between HOA patients with and without CTS. After adjustment for age and sex, the presence of CTS in the dominant hand was not statistically associated with grip strength disturbances (measured with the Jamar dynamometer), pinch strength (thumb index finger pinch), number of joints painful to pressure, and KL score.ConclusionThe risk factors for CTS in HOA are those known in the general population (hypothyroidism, obesity and metabolic syndrome). However, our study did not find any impact of CTS on the clinical signs and structural severity of HOA.References[1]Kim YH, Han EY, Kim J, Seo K-B, Jeon YT, Im SH. Associations between hand function and electrophysiological measurements in hand osteoarthritis patients of different ages with or without carpal tunnel syndrome. Sci Rep 2020;10:19278. https://doi.org/10.1038/s41598-020-74795-2.[2]Sellam J, Maheu E, Crema MD, Touati A, Courties A, Tuffet S, et al. The DIGICOD cohort: A hospital-based observational prospective cohort of patients with hand osteoarthritis - methodology and baseline characteristics of the population. Jt Bone Spine 2021;88:105171. https://doi.org/10.1016/j.jbspin.2021.105171.AcknowledgementsAll the patients who have accepted to participate to the DIGICOD cohort. All the investigators who manage or have managed patients’ recruitments, and the monitoring the clinical visits (Dr. Camille Deprouw, Dr. Sandra Desouches, Dr. Ariane Do, Dr. Emeline Gaigneux, Dr. Camille Glanowski, Dr. Karine Louati, Dr. Stéphanie Malbos, Dr. Sabine Trellu, Dr. Houda Ajlani, Dr. Juliette-Louise Petit and Dr. Clémence Gorlier all from the Rheumatology Department of AP–HP Saint-Antoine Hospital), the staff members of the URCEST and of the Centre des Ressources Biologiques from AP–HP Saint-Antoine Hospital.Funding of the DIGICOD cohortTRB Chemedica unrestricted research grantDisclosure of InterestsNone declared
Collapse
|
22
|
Voillequin S, Rozenberg P, Ravaud P, Rousseau A. Promptness of oxytocin administration for first-line treatment of postpartum hemorrhage: a national vignette-based study among midwives. BMC Pregnancy Childbirth 2022; 22:353. [PMID: 35461215 PMCID: PMC9034651 DOI: 10.1186/s12884-022-04648-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Accepted: 03/31/2022] [Indexed: 11/24/2022] Open
Abstract
Background Postpartum hemorrhage (PPH) remains a leading cause of maternal morbidity and mortality worldwide. Midwives play a key role in the initial management of PPH. Uterotonic agents are widely used in its prevention and treatment, with oxytocin the first-line agent. Nonetheless, a standardized guideline for optimal dose and rate of administration has not been clearly defined. The aim of this study was to investigate French midwives’ practices regarding first-line oxytocin treatment and the factors influencing its delayed administration. Methods This multicenter study was based on clinical vignettes of PPH management collected using an anonymous online questionnaire. A random sample of midwives from 145 maternity units in France from 15 randomly selected perinatal networks were invited to participate by email. The Previously validated case vignettes described two different scenarios of severe PPH. Vignette 1 described a typical immediate, severe PPH, and vignette 2 a less typical case of severe but gradual PPH They were constructed in three successive steps and included multiple-choice questions proposing several types of clinical practice options at each stage. For each vignette separately, we analyzed the lack of prompt oxytocin administration and the factors contributing to them, that is, characteristics of the midwives and organizational features of maternity units. Bivariate analysis and multivariable logistic regression analysis were applied. Results In all, 450 midwives from 87 maternity units provided complete responses. Lack of promptness was observed in 21.6% of responses (N = 97) in Vignette 1 and in 13.8% (N = 62) in Vignette 2 (p < .05). After multivariate analysis, the risk of delay was lower among with midwives working in university maternity hospitals (ORa 0.47, 95% 0.21, 0.97) and in units with 1500 to 2500 births per year (ORa 0.49, 95% CI 0.26, 0.90) for Vignette 1. We also noticed that delay increased with the midwives’ years of experience (per 10-year period) (ORa 1.30, 95% CI 1.01, 1.69). Conclusions This study using clinical vignettes showed delays in oxytocin administration for first-line treatment of PPH. Because delay in treatment is a major cause of preventable maternal morbidity in PPH, these findings suggest that continuing training of midwives should be considered, especially in small maternity units. Supplementary Information The online version contains supplementary material available at 10.1186/s12884-022-04648-5.
Collapse
Affiliation(s)
- S Voillequin
- Department of Obstetrics and Gynecology, Strasbourg University Hospital, Strasbourg, France. .,INSERM UMR1018 "Clinical Epidemiology Team", Research Center on Epidemiology and Population Health (CESP), UVSQ, Paris Saclay University, Villejuif, France. .,Midwifery Department, Strasbourg University, Strasbourg, France.
| | - P Rozenberg
- INSERM UMR1018 "Clinical Epidemiology Team", Research Center on Epidemiology and Population Health (CESP), UVSQ, Paris Saclay University, Villejuif, France.,Department of Obstetrics and Gynecology, Poissy-Saint Germain Hospital, Poissy, France
| | - Ph Ravaud
- INSERM UMR1153, Centre of Research Epidemiology and Statistics (CRESS), Université de Paris, Paris, France.,Center for Clinical Epidemiology, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpital Hôtel Dieu, Paris, France
| | - A Rousseau
- INSERM UMR1018 "Clinical Epidemiology Team", Research Center on Epidemiology and Population Health (CESP), UVSQ, Paris Saclay University, Villejuif, France.,Department of Obstetrics and Gynecology, Poissy-Saint Germain Hospital, Poissy, France
| |
Collapse
|
23
|
Guihot A, Plu I, Soulié C, Rousseau A, Nakid-Cordero C, Dorgham K, Parizot C, Litvinova E, Mayaux J, Malet I, Quentric P, Combadière B, Combadière C, Bonduelle O, Adam L, Rosenbaum P, Beurton A, Hémon P, Debré P, Vieillard V, Autran B, Seilhean D, Charlotte F, Marcelin AG, Gorochov G, Luyt CE. Memory CD4+ T-Cell Lymphocytic Angiopathy in Fatal Forms of COVID-19 Pulmonary Infection. Front Immunol 2022; 13:844727. [PMID: 35529881 PMCID: PMC9074842 DOI: 10.3389/fimmu.2022.844727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Accepted: 03/11/2022] [Indexed: 01/08/2023] Open
Abstract
The immunopathological pulmonary mechanisms leading to Coronavirus Disease (COVID-19)-related death in adults remain poorly understood. Bronchoalveolar lavage (BAL) and peripheral blood sampling were performed in 74 steroid and non-steroid-treated intensive care unit (ICU) patients (23-75 years; 44 survivors). Peripheral effector SARS-CoV-2-specific T cells were detected in 34/58 cases, mainly directed against the S1 portion of the spike protein. The BAL lymphocytosis consisted of T cells, while the mean CD4/CD8 ratio was 1.80 in non-steroid- treated patients and 1.14 in steroid-treated patients. Moreover, strong BAL SARS-CoV-2 specific T-cell responses were detected in 4/4 surviving and 3/3 non-surviving patients. Serum IFN-γ and IL-6 levels were decreased in steroid-treated patients when compared to non-steroid treated patients. In the lung samples from 3 (1 non-ICU and 2 ICU) additional deceased cases, a lymphocytic memory CD4 T-cell angiopathy colocalizing with SARS-CoV-2 was also observed. Taken together, these data show that disease severity occurs despite strong antiviral CD4 T cell-specific responses migrating to the lung, which could suggest a pathogenic role for perivascular memory CD4 T cells upon fatal COVID-19 pneumonia.
Collapse
Affiliation(s)
- Amélie Guihot
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département d’Immunologie, Paris, France
| | - Isabelle Plu
- Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France
| | - Cathia Soulié
- Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Laboratoire de Virologie, Paris, France
| | - Alice Rousseau
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Cecilia Nakid-Cordero
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Karim Dorgham
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Christophe Parizot
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département d’Immunologie, Paris, France
| | - Elena Litvinova
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département d’Immunologie, Paris, France
| | - Julien Mayaux
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Service de Médecine Intensive–Réanimation et Pneumologie, Paris, France
| | - Isabelle Malet
- Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Laboratoire de Virologie, Paris, France
| | - Paul Quentric
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Béhazine Combadière
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Christophe Combadière
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Olivia Bonduelle
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Lucille Adam
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Pierre Rosenbaum
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Alexandra Beurton
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Service de Médecine Intensive–Réanimation et Pneumologie, Paris, France
| | - Patrice Hémon
- LBAI, Hyperion platform, University of Brest, INSERM, CHU de Brest, Brest, France
| | - Patrice Debré
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Vincent Vieillard
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Brigitte Autran
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
| | - Danielle Seilhean
- Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département de Neuropathologie, Paris, France
| | - Frédéric Charlotte
- Assistance Publique-Hôpitaux de Paris (AP-HP), Service d’Anatomopathologie, Hôpital Pitié-Salpêtrière, Paris, France; Sorbonne Université, Paris, France
| | - Anne-Geneviève Marcelin
- Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique (iPLESP), AP-HP, Hôpital Pitié Salpêtrière, Laboratoire de Virologie, Paris, France
| | - Guy Gorochov
- Sorbonne Université INSERM, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Hôpital Pitié-Salpêtrière, Paris, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Département d’Immunologie, Paris, France
| | - Charles-Edouard Luyt
- Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpital Pitié–Salpêtrière, Service de Médecine Intensive Réanimation, Institut de Cardiologie, Paris, France
- Sorbonne Université, Inserm, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
| |
Collapse
|
24
|
Rousseau A, Stien C, Bordy JM, Blideanu V. Fricke-Xylenol orange-Gelatin gel characterization with dual wavelength cone-beam optical CT scanner for applications in stereotactic and dynamic radiotherapy. Phys Med 2022; 97:1-12. [PMID: 35313240 DOI: 10.1016/j.ejmp.2022.03.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 03/10/2022] [Accepted: 03/14/2022] [Indexed: 10/18/2022] Open
Abstract
PURPOSE This study is about the development of a new dual wavelength reading method of Fricke-Xylenol orange-Gelatin (FXG) gel dosimeters on the Vista16™ optical Computed Tomography (CT) scanner to perform 3D dose distribution measurements in stereotactic and dynamic radiotherapy treatments. METHODS The dosimetric characteristics of an optimized FXG gel composition and its optical CT readout have been evaluated. A dual wavelength reading method has been developed on the CT scanner at wavelengths 590 nm and 633 nm. Small-field dose profile measurements with FXG gel and microDiamond (PTW) detectors were compared by γ-index analysis (0.5%/0.5 mm) to validate this method. RESULTS This reading method exhibits linear calibration curves in the 0-4 Gy and 2-10 Gy dose ranges at 590 nm and 633 nm respectively. The absorbed dose values below 4 Gy, measured at 590 nm, and those above 4 Gy, measured at 633 nm, are combined to plot a complete profile. A γ passing rate of 93.4% was achieved. CONCLUSIONS The new reading method of FXG gel dosimeters has been implemented on the Vista16™ scanner to span absorbed doses representative of stereotactic and dynamic radiotherapy treatments and enable 3D measurements in tumor volumes and surrounding healthy tissues. Small-field profile measurements validated this reading method as FXG gel dosimeters and microDiamond detectors were in very close agreement. This dosimetric method is a promising candidate for 3D quality assurance end-to-end tests in stereotactic and dynamic radiotherapy.
Collapse
Affiliation(s)
- Alice Rousseau
- Université Paris-Saclay, CEA, List, Laboratoire National Henri Becquerel (LNE-LNHB), 91120 Palaiseau, France.
| | - Christel Stien
- Université Paris-Saclay, CEA, List, Laboratoire National Henri Becquerel (LNE-LNHB), 91120 Palaiseau, France.
| | - Jean-Marc Bordy
- Université Paris-Saclay, CEA, List, Laboratoire National Henri Becquerel (LNE-LNHB), 91120 Palaiseau, France.
| | - Valentin Blideanu
- Université Paris-Saclay, CEA, List, Laboratoire National Henri Becquerel (LNE-LNHB), 91120 Palaiseau, France.
| |
Collapse
|
25
|
Baron M, Soulié C, Lavolé A, Assoumou L, Abbar B, Fouquet B, Rousseau A, Veyri M, Samri A, Makinson A, Choquet S, Mazières J, Brosseau S, Autran B, Costagliola D, Katlama C, Cadranel J, Marcelin AG, Lambotte O, Spano JP, Guihot A. Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer. Cells 2022; 11:cells11061015. [PMID: 35326466 PMCID: PMC8946896 DOI: 10.3390/cells11061015] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2022] [Revised: 03/03/2022] [Accepted: 03/09/2022] [Indexed: 02/06/2023] Open
Abstract
The role of immune checkpoints (ICPs) in both anti-HIV T cell exhaustion and HIV reservoir persistence, has suggested that an HIV cure therapeutic strategy could involve ICP blockade. We studied the impact of anti-PD-1 therapy on HIV reservoirs and anti-viral immune responses in people living with HIV and treated for cancer. At several timepoints, we monitored CD4 cell counts, plasma HIV-RNA, cell associated (CA) HIV-DNA, EBV, CMV, HBV, HCV, and HHV-8 viral loads, activation markers, ICP expression and virus-specific T cells. Thirty-two patients were included, with median follow-up of 5 months. The CA HIV-DNA tended to decrease before cycle 2 (p = 0.049). Six patients exhibited a ≥0.5 log10 HIV-DNA decrease at least once. Among those, HIV-DNA became undetectable for 10 months in one patient. Overall, no significant increase in HIV-specific immunity was observed. In contrast, we detected an early increase in CTLA-4 + CD4+ T cells in all patients (p = 0.004) and a greater increase in CTLA-4+ and TIM-3 + CD8+ T cells in patients without HIV-DNA reduction compared to the others (p ≤ 0.03). Our results suggest that ICP replacement compensatory mechanisms might limit the impact of anti-PD-1 monotherapy on HIV reservoirs, and pave the way for combination ICP blockade in HIV cure strategies.
Collapse
Affiliation(s)
- Marine Baron
- INSERM U1135, CIMI, Département d’Immunologie, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, F-75013 Paris, France; (B.A.); (B.F.); (A.R.); (A.S.); (B.A.); (A.G.)
- Correspondence:
| | - Cathia Soulié
- INSERM UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Département de Virologie, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, F-75013 Paris, France; (C.S.); (A.-G.M.)
| | - Armelle Lavolé
- GRC #04 Theranoscan, Département de Pneumologie et Oncologie Thoracique, AP-HP, Hôpital Tenon, Sorbonne Université, F-75020 Paris, France; (A.L.); (J.C.)
| | - Lambert Assoumou
- INSERM UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne Université, F-75013 Paris, France; (L.A.); (D.C.)
| | - Baptiste Abbar
- INSERM U1135, CIMI, Département d’Immunologie, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, F-75013 Paris, France; (B.A.); (B.F.); (A.R.); (A.S.); (B.A.); (A.G.)
| | - Baptiste Fouquet
- INSERM U1135, CIMI, Département d’Immunologie, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, F-75013 Paris, France; (B.A.); (B.F.); (A.R.); (A.S.); (B.A.); (A.G.)
| | - Alice Rousseau
- INSERM U1135, CIMI, Département d’Immunologie, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, F-75013 Paris, France; (B.A.); (B.F.); (A.R.); (A.S.); (B.A.); (A.G.)
| | - Marianne Veyri
- Département d’Oncologie Médicale, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, F-75013 Paris, France; (M.V.); (J.-P.S.)
| | - Assia Samri
- INSERM U1135, CIMI, Département d’Immunologie, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, F-75013 Paris, France; (B.A.); (B.F.); (A.R.); (A.S.); (B.A.); (A.G.)
| | - Alain Makinson
- INSERM U1175, Département de Maladies Infectieuses, Centre Hospitalier Universitaire de Montpellier, Université de Montpellier, F-34090 Montpellier, France;
| | - Sylvain Choquet
- Département d’Hématologie Clinique, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, F-75013 Paris, France;
| | - Julien Mazières
- Département de Pneumologie, Centre Hospitalier Universitaire de Toulouse, F-31000 Toulouse, France;
| | - Solenn Brosseau
- Département de Pneumologie, AP-HP, Hôpital Bichat-Claude Bernard, F-75018 Paris, France;
| | - Brigitte Autran
- INSERM U1135, CIMI, Département d’Immunologie, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, F-75013 Paris, France; (B.A.); (B.F.); (A.R.); (A.S.); (B.A.); (A.G.)
| | - Dominique Costagliola
- INSERM UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Sorbonne Université, F-75013 Paris, France; (L.A.); (D.C.)
| | - Christine Katlama
- Département de Maladies Infectieuses, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, F-75013 Paris, France;
| | - Jacques Cadranel
- GRC #04 Theranoscan, Département de Pneumologie et Oncologie Thoracique, AP-HP, Hôpital Tenon, Sorbonne Université, F-75020 Paris, France; (A.L.); (J.C.)
| | - Anne-Geneviève Marcelin
- INSERM UMR_S 1136, Institut Pierre Louis d’Epidémiologie et de Santé Publique, Département de Virologie, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, F-75013 Paris, France; (C.S.); (A.-G.M.)
| | - Olivier Lambotte
- Département d’Immunologie Clinique, AP-HP, Hôpital Bicêtre, Université Paris-Saclay, F-94270 Le Kremlin Bicêtre, France;
- INSERM, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial Diseases (IDMIT/IMVA-HB), UMR1184, Université Paris-Saclay, F-94270 Le Kremlin Bicêtre, France
| | - Jean-Philippe Spano
- Département d’Oncologie Médicale, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, F-75013 Paris, France; (M.V.); (J.-P.S.)
| | - Amélie Guihot
- INSERM U1135, CIMI, Département d’Immunologie, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, F-75013 Paris, France; (B.A.); (B.F.); (A.R.); (A.S.); (B.A.); (A.G.)
| | | | | |
Collapse
|
26
|
Khalfa M, Oueslati A, Khirouni K, Gargouri M, Rousseau A, Lhoste J, Bardeau JF, Corbel G. Synthesis, structural and electrical characterization of a new organic inorganic bromide: [(C 3H 7) 4N] 2CoBr 4. RSC Adv 2022; 12:2798-2809. [PMID: 35425329 PMCID: PMC8979218 DOI: 10.1039/d1ra07965d] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2021] [Accepted: 01/04/2022] [Indexed: 11/21/2022] Open
Abstract
A new organic inorganic hybrid [TPA]2CoBr4, where TPA = [(C3H7)4N]+ (i.e., tetra-propyl-ammonium) compound has been synthesized by slow evaporation method at room temperature. Single crystal X-ray diffraction (SC-XRD), X-ray powder diffraction (XRPD), thermal analyses, vibrational and complex impedance spectroscopy have been used to characterize both structural, thermal, electrical properties. [TPA]2CoBr4 crystallizes in the monoclinic system (C2/c space group) with the following cell parameters: a = 33.145 (5) Å, b = 14.234 (3) Å, c = 15.081 (2) Å and β = 110.207 (5)°. In the crystal structure, the organic TPA cations which form layers stacked along the a-axis, are separated from each other by inorganic tetrahedral [CoBr4]2- anions. The XRPD pattern confirms both the high purity of the sample and the crystalline nature of the powder. The differential scanning calorimetry (DSC) analysis shows an endothermic peak at 394 K upon heating which is ascribed to a structural phase transition since no decomposition of the titled compound is evidenced by thermogravimetric analysis. The ac conductivity and the dielectric properties confirm the presence of the phase transition. At the structural phase transition around 394 K, a change from a quantum mechanical tunneling to a correlated barrier hopping conduction models is determined from the temperature dependence of the exponent s of the Jonscher's power law. The analysis of complex impedance spectra shows that the electrical properties of the material are heavily dependent on frequency and temperature, indicating a relaxation phenomenon and semiconductor-type behavior. One single semicircle is detectable in the Nyquist plots of the complex impedance spectra which can be satisfactorily fitted with a combination R//CPE elements assigned to the bulk response. This behavior suggests that the sample is electrically homogeneous. Capacitance analysis proves the high effective permittivity at radio frequencies in the sample.
Collapse
Affiliation(s)
- M Khalfa
- Laboratoire de Physique des Matériaux et des Nanomatériaux appliquée à l'Environnement, Faculté des Sciences de Gabès cité Erriadh 6079 Gabès Tunisia
| | - A Oueslati
- Laboratory for Spectroscopic Characterization and Optics of Materials, Faculty of Sciences, University of Sfax B. P. 1171 3000 Sfax Tunisia
| | - K Khirouni
- Laboratoire de Physique des Matériaux et des Nanomatériaux appliquée à l'Environnement, Faculté des Sciences de Gabès cité Erriadh 6079 Gabès Tunisia
| | - M Gargouri
- Laboratory for Spectroscopic Characterization and Optics of Materials, Faculty of Sciences, University of Sfax B. P. 1171 3000 Sfax Tunisia
| | - A Rousseau
- Institut des Molécules et Matériaux du Mans (IMMM), UMR-6283 CNRS, Le Mans Université Avenue Olivier Messiaen 72085 Le Mans Cedex 9 France
| | - J Lhoste
- Institut des Molécules et Matériaux du Mans (IMMM), UMR-6283 CNRS, Le Mans Université Avenue Olivier Messiaen 72085 Le Mans Cedex 9 France
| | - J-F Bardeau
- Institut des Molécules et Matériaux du Mans (IMMM), UMR-6283 CNRS, Le Mans Université Avenue Olivier Messiaen 72085 Le Mans Cedex 9 France
| | - G Corbel
- Institut des Molécules et Matériaux du Mans (IMMM), UMR-6283 CNRS, Le Mans Université Avenue Olivier Messiaen 72085 Le Mans Cedex 9 France
| |
Collapse
|
27
|
Tibi K, Riou B, Barreau E, Labétoulle M, Rousseau A. [Retinal arterial macroaneurysm on OCT angiography]. J Fr Ophtalmol 2022; 45:251-252. [PMID: 35000799 DOI: 10.1016/j.jfo.2021.08.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Accepted: 08/13/2021] [Indexed: 10/19/2022]
Affiliation(s)
- K Tibi
- Service d'ophtalmologie, CHU Bicêtre, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - B Riou
- Service d'ophtalmologie, CHU Bicêtre, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - E Barreau
- Service d'ophtalmologie, CHU Bicêtre, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - M Labétoulle
- Service d'ophtalmologie, CHU Bicêtre, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - A Rousseau
- Service d'ophtalmologie, CHU Bicêtre, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France.
| |
Collapse
|
28
|
Schaeffer M, Ballonzoli L, Gaucher D, Arndt C, Angioi-Duprez K, Baudonnet R, Bodaghi B, Bron A, Chiambaretta F, Cimon B, Chiquet C, Creuzot-Garcher C, Daien V, Deleplanque AS, Fricker-Hidalgo H, Hadjadj E, Houze S, Ifrah T, Korobelnik JF, Labalette P, Le Lez ML, L’Ollivier C, Mercie M, Mouriaux F, Paris L, Pelloux H, Pomares C, Quintyn JC, Rougier MB, Rousseau A, Soler V, Talmud M, Villena I, Villard O, Speeg-Schatz C, Bourcier T, Sauer A. Prise en charge de la toxoplasmose oculaire en France : résultats d’une étude Delphi modifiée. J Fr Ophtalmol 2022; 45:413-422. [DOI: 10.1016/j.jfo.2021.11.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 11/08/2021] [Accepted: 11/08/2021] [Indexed: 11/29/2022]
|
29
|
Rousseau A, Stien C, Baumann M, Bordy JM, Blideanu V. Dual wavelength reading method of Fricke-Xylenol orange-Gelatin gel dosimeters with cone-beam optical CT scanner for applications in stereotactic radiotherapy. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00174-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
30
|
Bruneau L, Lenclume V, Maillot A, Rousseau A, Lagrange-Xélot M, Allou N, Gérardin P. Exhaustive assessment of Reunion Island inpatients with COVID-19 during the first wave. Infect Dis Now 2021; 52:112-116. [PMID: 34706299 PMCID: PMC8542257 DOI: 10.1016/j.idnow.2021.10.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 05/18/2021] [Accepted: 10/20/2021] [Indexed: 12/01/2022]
Affiliation(s)
- L Bruneau
- National institute of Health and Medical Research (INSERM) Center for Clinical Investigation (CIC) 1410 Clinical Epidemiology, Centre Hospitalier Universitaire, Saint Pierre, Reunion Island, France; Department of Public health and Research Support, Methodological Support and Biostatistics Unit, Centre Hospitalier Universitaire, Saint Denis, Reunion Island, France.
| | - V Lenclume
- National institute of Health and Medical Research (INSERM) Center for Clinical Investigation (CIC) 1410 Clinical Epidemiology, Centre Hospitalier Universitaire, Saint Pierre, Reunion Island, France.
| | - A Maillot
- National institute of Health and Medical Research (INSERM) Center for Clinical Investigation (CIC) 1410 Clinical Epidemiology, Centre Hospitalier Universitaire, Saint Pierre, Reunion Island, France.
| | - A Rousseau
- Department of Public health and Research Support, Methodological Support and Biostatistics Unit, Centre Hospitalier Universitaire, Saint Denis, Reunion Island, France.
| | - M Lagrange-Xélot
- Department of Infectious Diseases, Centre Hospitalier Universitaire, Saint Denis, Reunion Island, France.
| | - N Allou
- Intensive Care Unit, Centre Hospitalier Universitaire, Saint Denis, Reunion Island, France.
| | - P Gérardin
- National institute of Health and Medical Research (INSERM) Center for Clinical Investigation (CIC) 1410 Clinical Epidemiology, Centre Hospitalier Universitaire, Saint Pierre, Reunion Island, France.
| |
Collapse
|
31
|
Azria E, Rousseau A, Anselem O, Bonnet MP, Deneux C, Sauvegrain P, Richetin J. Racial implicit bias among obstetricians and midwives, and information on Down syndrome screening. Eur J Public Health 2021. [DOI: 10.1093/eurpub/ckab164.386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background and objectives
Previous studies showed disparities in prenatal screening for Down syndrome according to the maternal place of birth. Among the factors that might be involved in these differences, social cognition offers the concept of implicit bias (IB) used to describe the fact of having attitudes towards people or associating stereotypes with them without necessarily conscious knowledge. In line with theoretical and empirical contributions in social psychology that postulate and demonstrate the role of automatic processes in determining behavior, IBs often predict how individuals behave more accurately than conscious values. The existence of IB among health professionals has been demonstrated in emergency care or pain management. To our knowledge, no study of IB has been conducted in Europe, nor in the field of perinatal care. Thus, our objectives were to test for IBs towards African women in terms of evaluation (negative bias) and strength (positive bias) among perinatal health professionals and test whether these IBs predicted treatment recommendations toward African vs. French patients.
Methods
Through online data collection, 887 perinatal care practicians (obstetrician-gynecologists, midwives) answered a series of case vignettes depicting African vs. French patients, with one specific to a Down syndrome screening situation. Then, participants completed two Implicit Association Tests to assess valence and strength IBs toward African vs. French women.
Results
81.3% of the sample showed an implicit evaluative preference for French over African women, and 60.2% had an implicit perception of African women as stronger than French. However, decision toward Down syndrome screening were not influenced by the patient's origin nor by the healthcare professional implicit bias.
Conclusions
Perinatal practicians seem to have implicit biases toward African women, but the way they provide information regarding Down Syndrome screening is not affected.
Collapse
Affiliation(s)
- E Azria
- UMR1153 EPOPé, INSERM Université de Paris, Paris, France
- Department of Obstetrics, Groupe Hospitalier Paris Saint Joseph, Paris, France
| | - A Rousseau
- Midwifery Department, Versailles Saint Quentin University, Montigny-le-Bretonneux, France
- EA 7285, Versailles Saint Quentin University, Montigny le Bretonneux, France
| | - O Anselem
- Department of Obstetrics and Gynaecology, Port Royal, APHP, Paris, France
| | - MP Bonnet
- UMR1153 EPOPé, INSERM Université de Paris, Paris, France
- Department of Obstetrics, Trousseau, APHP, Paris, France
| | - C Deneux
- UMR1153 EPOPé, INSERM Université de Paris, Paris, France
| | - P Sauvegrain
- UMR1153 EPOPé, INSERM Université de Paris, Paris, France
| | - J Richetin
- Department of Psychology, University of Milan Bicocca, Milan, Italy
| |
Collapse
|
32
|
Bastelica P, Labetoulle M, Noel N, Barreau E, Matonti F, Jourde Chiche N, Rousseau A, Benichou J. [Retinal involvement in hypocomplementemic urticarial vasculitis (McDuffie syndrome): Report of two cases]. J Fr Ophtalmol 2021; 44:e587-e590. [PMID: 34452765 DOI: 10.1016/j.jfo.2021.02.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Revised: 01/16/2021] [Accepted: 02/01/2021] [Indexed: 11/29/2022]
Affiliation(s)
- P Bastelica
- Service d'ophtalmologie, hôpital Bicêtre, université Paris-Sud, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - M Labetoulle
- Service d'ophtalmologie, hôpital Bicêtre, université Paris-Sud, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France; Department of Immunology of viral and auto-immune disease (IMVA DSV, iMETI, IDMIT), UMR1184, CEA, 18, route du Panorama, 92260 Fontenay-aux-Roses, France
| | - N Noel
- Department of Immunology of viral and auto-immune disease (IMVA DSV, iMETI, IDMIT), UMR1184, CEA, 18, route du Panorama, 92260 Fontenay-aux-Roses, France; Service d'immunologie clinique, hôpital Bicêtre, université Paris-Sud, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - E Barreau
- Service d'ophtalmologie, hôpital Bicêtre, université Paris-Sud, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France
| | - F Matonti
- Centre Monticelli Paradis, 433bis rue Paradis, 13008 Marseille, France; Université Aix-Marseille, CNRS, INT, Institut de neurosciences de la Timone, 27, boulevard Jean-Moulin, 13385 Marseille cedex 05, France
| | - N Jourde Chiche
- Université Aix-Marseille, C2VN, Inserm, INRA ; centre de néphrologie et transplantation rénale, hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France
| | - A Rousseau
- Service d'ophtalmologie, hôpital Bicêtre, université Paris-Sud, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France; Department of Immunology of viral and auto-immune disease (IMVA DSV, iMETI, IDMIT), UMR1184, CEA, 18, route du Panorama, 92260 Fontenay-aux-Roses, France
| | - J Benichou
- Service d'ophtalmologie, hôpital Bicêtre, université Paris-Sud, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France.
| |
Collapse
|
33
|
Toigo V, Marcuzzi D, Serianni G, Boldrin M, Chitarin G, Bello SD, Grando L, Luchetta A, Pasqualotto R, Zaccaria P, Zanotto L, Agnello R, Agostinetti P, Agostini M, Antoni V, Aprile D, Barbisan M, Battistella M, Berton G, Bigi M, Brombin M, Candeloro V, Canton A, Casagrande R, Cavallini C, Cavazzana R, Cordaro L, Cruz N, Palma MD, Dan M, De Lorenzi A, Delogu R, De Muri M, Denizeau S, Fadone M, Fellin F, Ferro A, Gaio E, Gasparini F, Gasparrini C, Gnesotto F, Jain P, Krastev P, Lopez-Bruna D, Lorenzini R, Maistrello A, Manduchi G, Manfrin S, Marconato N, Martines E, Martini G, Martini S, Milazzo R, Patton T, Pavei M, Peruzzo S, Pilan N, Pimazzoni A, Poggi C, Pomaro N, Pouradier-Duteil B, Recchia M, Rigoni-Garola A, Rizzolo A, Sartori E, Shepherd A, Siragusa M, Sonato P, Sottocornola A, Spada E, Spagnolo S, Spolaore M, Taliercio C, Terranova D, Tinti P, Tomsič P, Trevisan L, Ugoletti M, Valente M, Vignando M, Zagorski R, Zamengo A, Zaniol B, Zaupa M, Zuin M, Cavenago M, Boilson D, Rotti C, Veltri P, Decamps H, Dremel M, Graceffa J, Geli F, Urbani M, Zacks J, Bonicelli T, Paolucci F, Garbuglia A, Agarici G, Gomez G, Gutierrez D, Kouzmenko G, Labate C, Masiello A, Mico G, Moreno JF, Pilard V, Rousseau A, Simon M, Kashiwagi M, Tobari H, Watanabe K, Maejima T, Kojima A, Oshita E, Yamashita Y, Konno S, Singh M, Chakraborty A, Patel H, Singh N, Fantz U, Bonomo F, Cristofaro S, Heinemann B, Kraus W, Wimmer C, Wünderlich D, Fubiani G, Tsumori K, Croci G, Gorini G, McCormack O, Muraro A, Rebai M, Tardocchi M, Giacomelli L, Rigamonti D, Taccogna F, Bruno D, Rutigliano M, D'Arienzo M, Tonti A, Panin F. On the road to ITER NBIs: SPIDER improvement after first operation and MITICA construction progress. Fusion Engineering and Design 2021. [DOI: 10.1016/j.fusengdes.2021.112622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
Fouquet G, Thongsa-Ad U, Lefevre C, Rousseau A, Tanhuad N, Khongkla E, Saengsawang W, Anurathapan U, Hongeng S, Maciel TT, Hermine O, Bhukhai K. Iron-loaded transferrin potentiates erythropoietin effects on erythroblast proliferation and survival: a novel role through transferrin receptors. Exp Hematol 2021; 99:12-20.e3. [PMID: 34077792 DOI: 10.1016/j.exphem.2021.05.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2021] [Revised: 05/16/2021] [Accepted: 05/26/2021] [Indexed: 12/21/2022]
Abstract
Red blood cell production, or erythropoiesis, is a proliferative process that requires tight regulation. Erythropoietin (Epo) is a glycoprotein cytokine that plays a major role in erythropoiesis by triggering erythroid progenitors/precursors of varying sensitivity. The concentration of Epo in bone marrow is hypothesized to be suboptimal, and the survival of erythroid cells has been suggested to depend on Epo sensitivity. However, the key factors that control Epo sensitivity remain unknown. Two types of transferrin receptors (TfRs), TfR1 and TfR2, are known to play a role in iron uptake in erythroid cells. Here, we hypothesized that TfRs may additionally modulate Epo sensitivity during erythropoiesis by modulating Epo receptor (EpoR) signaling. Using an Epo-sensitive UT-7 (UT7/Epo) erythroid cell and human erythroid progenitor cell models, we report that iron-loaded transferrin, that is, holo-transferrin (holo-Tf), synergizes with suboptimal Epo levels to improve erythroid cell survival, proliferation, and differentiation. This is accomplished via the major signaling pathways of erythropoiesis, which include signal transducer and activator of transcription 5 (STAT5), mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK), and phosphoinositide-3-kinase (PI3K)/AKT. Furthermore, we found that this cooperation is improved by, but does not require, the internalization of TfR1. Interestingly, we observed that loss of TfR2 stabilizes EpoR levels and abolishes the beneficial effects of holo-Tf. Overall, these data reveal novel signaling properties of TfRs, which involve the regulation of erythropoiesis through EpoR signaling.
Collapse
Affiliation(s)
- Guillemette Fouquet
- Institut Hospitalo-Universitaire (IHU) Imagine, Université Sorbonne Paris cité, Assistance Publique-Hôpitaux de Paris, Hôpital Necker, Paris, France; INSERM U1163, Université Paris Descartes, Faculté de Médecine, Hôpital Necker, Paris, France; Laboratory of Excellence GReX, Paris, France
| | | | - Carine Lefevre
- Laboratory of Excellence GReX, Paris, France; INSERM U1016, Institut Cochin, Centre National de la Recherche Scientifique (CNRS) UMR8104, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Alice Rousseau
- INSERM U1016, Institut Cochin, Centre National de la Recherche Scientifique (CNRS) UMR8104, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Nopmullee Tanhuad
- Department of Physiology, Faculty of Science, Mahidol University, Bangkok, Thailand
| | - Ekkaphot Khongkla
- Department of Physiology, Faculty of Science, Mahidol University, Bangkok, Thailand
| | - Witchuda Saengsawang
- Department of Physiology, Faculty of Science, Mahidol University, Bangkok, Thailand
| | - Usanarat Anurathapan
- Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Suradej Hongeng
- Department of Pediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Thiago T Maciel
- Institut Hospitalo-Universitaire (IHU) Imagine, Université Sorbonne Paris cité, Assistance Publique-Hôpitaux de Paris, Hôpital Necker, Paris, France; INSERM U1163, Université Paris Descartes, Faculté de Médecine, Hôpital Necker, Paris, France; Laboratory of Excellence GReX, Paris, France
| | - Olivier Hermine
- Institut Hospitalo-Universitaire (IHU) Imagine, Université Sorbonne Paris cité, Assistance Publique-Hôpitaux de Paris, Hôpital Necker, Paris, France; INSERM U1163, Université Paris Descartes, Faculté de Médecine, Hôpital Necker, Paris, France; Laboratory of Excellence GReX, Paris, France; Service d'Hématologie clinique adultes, Assistance Publique-Hôpitaux de Paris, Hôpital Necker, Paris, France
| | - Kanit Bhukhai
- Institut Hospitalo-Universitaire (IHU) Imagine, Université Sorbonne Paris cité, Assistance Publique-Hôpitaux de Paris, Hôpital Necker, Paris, France; INSERM U1163, Université Paris Descartes, Faculté de Médecine, Hôpital Necker, Paris, France; Laboratory of Excellence GReX, Paris, France; Department of Physiology, Faculty of Science, Mahidol University, Bangkok, Thailand.
| |
Collapse
|
35
|
Mace T, Baldini N, Rousseau A, Haution D, Kün-Darbois JD. Cavernous venous malformation of the lacrimal gland. J Fr Ophtalmol 2021; 44:799-803. [PMID: 34020812 DOI: 10.1016/j.jfo.2020.09.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2020] [Accepted: 09/03/2020] [Indexed: 11/17/2022]
Abstract
BACKGROUND Cavernous venous malformation (CVM) is a common benign vascular lesion of the orbit. It was previously known as "orbital cavernous hemangioma". Localization within the lacrimal gland is extremely rare. CASE PRESENTATION We describe the case of a 76-year-old man with an asymptomatic CVM of the left lacrimal gland incidentally discovered on a routine MRI. A curative and diagnostic en bloc surgical resection was performed, allowing for histological diagnosis. CONCLUSIONS CVM of the lacrimal gland is extremely rare and usually asymptomatic. Proptosis is the main symptom. On MRI, the lesion appears hypointense with heterogeneous enhancement after Gadolinium injection on T1-weighted imaging and hyperintense on T2 STIR-weighted imaging. Histological examination is mandatory for the diagnosis. Surgical resection is usually performed.
Collapse
Affiliation(s)
- T Mace
- Department of maxillofacial surgery, Angers university hospital, 4, rue Larrey, 49933 Angers cedex, France; Department of ophthalmology, Angers university hospital, 4, rue Larrey, 49933 Angers cedex, France.
| | - N Baldini
- Department of maxillofacial surgery, Angers university hospital, 4, rue Larrey, 49933 Angers cedex, France
| | - A Rousseau
- Department of pathology, Angers university hospital, 4, rue Larrey, 49933 Angers cedex, France; Faculty of medicine, Angers university, 28, rue Roger-Amsler, 49045 Angers cedex 01, France
| | - D Haution
- Department of ophthalmology, Angers university hospital, 4, rue Larrey, 49933 Angers cedex, France
| | - J-D Kün-Darbois
- Department of maxillofacial surgery, Angers university hospital, 4, rue Larrey, 49933 Angers cedex, France; Faculty of medicine, Angers university, 28, rue Roger-Amsler, 49045 Angers cedex 01, France
| |
Collapse
|
36
|
Remongin PE, Rousseau A, Best AL, Ben Hadj Salah W, Legrand M, Benichou J, Barreau E, Labetoulle M. [Multimodal evaluation of the ocular surface using a the new Lacrydiag device]. J Fr Ophtalmol 2021; 44:313-320. [PMID: 33583607 DOI: 10.1016/j.jfo.2020.06.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2020] [Revised: 06/10/2020] [Accepted: 06/22/2020] [Indexed: 10/22/2022]
Abstract
INTRODUCTION Dry eye disease is a very frequent condition with a significant impact on patients' quality of life. The most common clinical sign is fluorescein break up time (BUT). Recently, non-invasive measurement of BUT (NIBUT) by Placido disc analysis has been proposed to replace FBUT. We performed an automated NIBUT analysis using Lacrydiag and compared the values obtained with other typical dry eye criteria. METHODS AND MATERIALS A retrospective study was carried out in the Bicêtre ophthalmology department from July 1 through October 30. Dry eye patients over 18 years of age with Oxford scores>1 and OSDI scores>22 were included. They underwent slit lamp examination to determine fluorescein BUT, Oxford and Arita MGD scores. On the same day, they were tested with the Lacrydiag to assess NIBUT, tear lake height and meibography. OSDI and Schirmer's testing were performed on the date of examination. In this study, only patients' right eyes were included. The correlation between NIBUT and OSDI, Schirmer's testing and tear lake height was analyzed by Pearson's test. The correlation between NIBUT and fluorescein BUT was analysed by both Pearson and Bland-Altman statistical tests. RESULTS Thirty right eyes (21 women, 9 men) were included. The mean age was 62.3 years (SD 16.0), mean OSDI 49.4 (SD=20.1), mean Oxford score 3.33 (SD 2.1), mean NIBUT 6.91sec (SD 3.4), and mean FBUT 3.6sec (SD 1.8). The NIBUT and FBUT were significantly correlated (R=0.139; P=0.042), with an even more significant concordance (r=0.55; P=0.001) on Bland-Altman graphic analysis, but the mean NIBUT was 2.7 seconds higher than the FBUT (P=0.001 on Bland-Altman analysis). In addition, NIBUT was correlated with the Oxford score (R=0.156; P=0.031), but not with Schirmer I score (R=0.120; P=0.061), OSDI score (R=0.018; P=0.48), tear lake height (R=0.04; P=0.148), or Arita meibomian gland dysfunction score (R=0; P=0.933). CONCLUSION NIBUT is a possible alternative to FBUT for the measurement of tear film stability, with the advantage of lack of dependence on the amount of fluorescein instilled. In addition, modern imaging methods allow for automated, and thus reproducible, measurement. However, its role in the diagnostic tool kit remains to be precisely defined, especially given its weak correlation with other markers of dry eye and its significant difference from FBUT. The definitive diagnosis of dry eye thus remains based on the combined analysis of signs and symptoms.
Collapse
Affiliation(s)
- P-E Remongin
- Service d'Ophtalmologie, CHU Bicetre, AP-HP, université Paris-Saclay, 94275 Le Kremlin-Bicêtre, France
| | - A Rousseau
- Service d'Ophtalmologie, CHU Bicetre, AP-HP, université Paris-Saclay, 94275 Le Kremlin-Bicêtre, France
| | - A-L Best
- Service d'Ophtalmologie, CHU Bicetre, AP-HP, université Paris-Saclay, 94275 Le Kremlin-Bicêtre, France
| | - W Ben Hadj Salah
- Service d'Ophtalmologie, CHU Bicetre, AP-HP, université Paris-Saclay, 94275 Le Kremlin-Bicêtre, France
| | - M Legrand
- Service d'Ophtalmologie, CHU Bicetre, AP-HP, université Paris-Saclay, 94275 Le Kremlin-Bicêtre, France
| | - J Benichou
- Service d'Ophtalmologie, CHU Bicetre, AP-HP, université Paris-Saclay, 94275 Le Kremlin-Bicêtre, France
| | - E Barreau
- Service d'Ophtalmologie, CHU Bicetre, AP-HP, université Paris-Saclay, 94275 Le Kremlin-Bicêtre, France
| | - M Labetoulle
- Service d'Ophtalmologie, CHU Bicetre, AP-HP, université Paris-Saclay, 94275 Le Kremlin-Bicêtre, France; Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases. IDMIT Infrastructure. CEA,Université Paris Saclay, Inserm U1184, 18, route du Panorama, 92265 Fontenay-aux-Roses cedex, France.
| |
Collapse
|
37
|
Maestri F, Legrand M, Da Cunha E, Best AL, Benichou J, Barreau E, Labetoulle M, Rousseau A. [Micropulsed diode laser transscleral cyclophotocoagulation: An effective technique whose role remains to be defined]. J Fr Ophtalmol 2021; 44:350-357. [PMID: 33487446 DOI: 10.1016/j.jfo.2020.09.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 09/01/2020] [Accepted: 09/03/2020] [Indexed: 11/16/2022]
Abstract
Micropulse Transscleral Cyclophotocoagulation (MP-TSCP) is a recently developed cyclodestructive procedure less aggressive than conventional TSCP. In this study, we aimed to evaluate the safety and efficacy of MP-TSCP in a real-life setting. MATERIAL AND METHODS We retrospectively included all MP-TSCP cases performed in the Bicêtre Hospital Ophthalmology department between January 2017 and September 2019. Intraocular pressure (IOP) and hypotensive medications were recorded preoperatively, at month 1, 3, 6 and at the conclusion of follow-up, as well as postoperative adverse events. Success was defined as an IOP between 6 and 21mmHg with a decrease of at least one medication or an IOP reduction>20%. RESULTS Thirty eyes (28 patients) were included. Preoperative IOP was 27.2±10.6mmHg, with 3.5±0.6 hypotensive medications, the mean deviation on the Humphrey 24-2 visual field was -21.9±6.9dB, and 43% of eyes had a past history of filtering surgery. The mean follow-up was 13.5±8.1 months. Eleven patients (37%) had to be retreated with MP-TSCP during follow-up. At 3 and 6 months and at the conclusion of follow-up, the IOP was 18.3±7.3mmHg (-33%; P<0.0001), 22.5±11.8mmHg, (-17%; P=0.052), 22.7±12.0mmHg (-16,5%; P<0.050), respectively. The success rates were 57%, 50% et 53% at 3 months, 6 months and at the conclusion of follow-up, respectively. Severe adverse events included 3 cases of corneal ulcers and 2 cases of severe but transient ocular hypotony without visual impairment. CONCLUSION MP-TSCP is an effective procedure for severe and/or refractory glaucoma, but retreatments are required in more than one-third of cases. Further studies are warranted to define factors predictive of success and indications for retreatment.
Collapse
Affiliation(s)
- F Maestri
- Service d'Ophtalmologie, CHU Bicêtre, Hôpital Bicêtre, Université Paris-Saclay, Réseau Ophtara: maladies rares en ophtalmologie, 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France
| | - M Legrand
- Service d'Ophtalmologie, CHU Bicêtre, Hôpital Bicêtre, Université Paris-Saclay, Réseau Ophtara: maladies rares en ophtalmologie, 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France
| | - E Da Cunha
- Service d'Ophtalmologie, CHU Bicêtre, Hôpital Bicêtre, Université Paris-Saclay, Réseau Ophtara: maladies rares en ophtalmologie, 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France
| | - A-L Best
- Service d'Ophtalmologie, CHU Bicêtre, Hôpital Bicêtre, Université Paris-Saclay, Réseau Ophtara: maladies rares en ophtalmologie, 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France
| | - J Benichou
- Service d'Ophtalmologie, CHU Bicêtre, Hôpital Bicêtre, Université Paris-Saclay, Réseau Ophtara: maladies rares en ophtalmologie, 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France
| | - E Barreau
- Service d'Ophtalmologie, CHU Bicêtre, Hôpital Bicêtre, Université Paris-Saclay, Réseau Ophtara: maladies rares en ophtalmologie, 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France
| | - M Labetoulle
- Service d'Ophtalmologie, CHU Bicêtre, Hôpital Bicêtre, Université Paris-Saclay, Réseau Ophtara: maladies rares en ophtalmologie, 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France
| | - A Rousseau
- Service d'Ophtalmologie, CHU Bicêtre, Hôpital Bicêtre, Université Paris-Saclay, Réseau Ophtara: maladies rares en ophtalmologie, 78, rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France.
| |
Collapse
|
38
|
Drisya KT, Edely M, Solís-López M, Jantrania A, Auguste S, Rousseau A, Casteneda H, Velumani S, Kassiba A. Structural features and morphology of titanium dioxide–bismuth vanadate heterojunctions. CrystEngComm 2021. [DOI: 10.1039/d1ce00982f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Titanium dioxide TiO2 (TO) and bismuth vanadate BiVO4 (BVO) are promising photoactive semiconducting oxides for heterogeneous photocatalysis devoted to water treatment, pollutant degradation and water splitting processes.
Collapse
Affiliation(s)
- K. T. Drisya
- Department of Electrical Engineering (SEES), Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Av. IPN 2508, Col. San Pedro Zacatenco, Ciudad de México, C.P 07360, Mexico
- Institute of Molecules and Materials of Le Mans UMR-CNRS 6283, Le Mans University, 70285 Le Mans, France
| | - M. Edely
- Institute of Molecules and Materials of Le Mans UMR-CNRS 6283, Le Mans University, 70285 Le Mans, France
| | - M. Solís-López
- Department of Electrical Engineering (SEES), Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Av. IPN 2508, Col. San Pedro Zacatenco, Ciudad de México, C.P 07360, Mexico
| | - A. Jantrania
- Department of Biological and Agricultural Engineering, Agrilife Extension, Texas A & M University, College Station, Texas 77843, USA
| | - S. Auguste
- Institute of Molecules and Materials of Le Mans UMR-CNRS 6283, Le Mans University, 70285 Le Mans, France
| | - A. Rousseau
- Institute of Molecules and Materials of Le Mans UMR-CNRS 6283, Le Mans University, 70285 Le Mans, France
| | - H. Casteneda
- Department of Materials Science and Engineering, Texas A&M University, College Station, 77802, Texas, USA
| | - S. Velumani
- Department of Electrical Engineering (SEES), Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Av. IPN 2508, Col. San Pedro Zacatenco, Ciudad de México, C.P 07360, Mexico
| | - A. Kassiba
- Institute of Molecules and Materials of Le Mans UMR-CNRS 6283, Le Mans University, 70285 Le Mans, France
| |
Collapse
|
39
|
Memmi B, Valleix S, Bourcier T, Labetoulle M, Rousseau A. Dystrophie granulaire: pas toujours facile à classifier…. J Fr Ophtalmol 2020; 43:e361-e363. [DOI: 10.1016/j.jfo.2020.02.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Revised: 02/20/2020] [Accepted: 02/25/2020] [Indexed: 10/23/2022]
|
40
|
Devilliers MJ, Ben Hadj Salah W, Barreau E, Da Cunha E, M'Garrech M, Bénichou J, Labetoulle M, Rousseau A. [Ocular manifestations of viral diseases]. Rev Med Interne 2020; 42:401-410. [PMID: 33168354 PMCID: PMC7646372 DOI: 10.1016/j.revmed.2020.08.022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2020] [Revised: 08/07/2020] [Accepted: 08/30/2020] [Indexed: 01/08/2023]
Abstract
Les infections virales peuvent toucher l’ensemble des tuniques oculaires et mettre en jeu la fonction visuelle à plus ou moins courte terme. Les kératites et kérato-uvéites liées au virus HSV-1 sont les atteintes les plus fréquentes. Les récurrences entraînent une opacification cornéenne irréversible qui en fait la première cause de cécité d’origine infectieuse dans les pays occidentaux, et justifient un traitement antiviral préventif au long cours. Le zona ophtalmique (10 à 20 % des zonas), peut s’accompagner d’atteintes oculaires sévères (kératites, kérato-uvéites), dont 30 % deviennent chroniques/récurrentes, et de douleurs post-zostériennes, redoutables dans le territoire trigéminé. Les rétinites nécrosantes liées aux herpesvirus (HSV, VZV, CMV), sont rares mais constituent des urgences fonctionnelles absolues nécessitant un traitement antiviral par voie intraveineuse et intravitréenne. Les conjonctivites à adénovirus constituent la première cause de conjonctivite infectieuse. Le plus souvent bénignes, elles sont extrêmement contagieuses et peuvent se compliquer de lésions cornéennes invalidantes persistant plusieurs mois, voire années. Certaines arboviroses s’accompagnent de manifestations oculaires inflammatoires. Dans le cas du Zika, les infections congénitales peuvent se compliquer d’atrophie maculaire et/ou optique. Les conjonctivites sont très fréquentes à la phase aiguë de la maladie à virus Ebola, dont 15 % des survivants présentent des atteintes inflammatoires chroniques sévères liées à la persistance du virus dans les tissus uvéaux. Enfin, dans le cadre de la COVID-19, les conjonctivites ne sont pas très fréquentes mais peuvent être inaugurales, voire au premier plan et sont associées à une excrétion virale lacrymale qui doit faire prendre toutes les précautions.
Collapse
Affiliation(s)
- M-J Devilliers
- Service d'ophtalmologie, CHU de Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, CRMR OPHTARA (maladies rares en ophtalmologie), 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France
| | - W Ben Hadj Salah
- Service d'ophtalmologie, CHU de Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, CRMR OPHTARA (maladies rares en ophtalmologie), 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France
| | - E Barreau
- Service d'ophtalmologie, CHU de Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, CRMR OPHTARA (maladies rares en ophtalmologie), 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France
| | - E Da Cunha
- Service d'ophtalmologie, CHU de Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, CRMR OPHTARA (maladies rares en ophtalmologie), 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France
| | - M M'Garrech
- Service d'ophtalmologie, CHU de Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, CRMR OPHTARA (maladies rares en ophtalmologie), 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France
| | - J Bénichou
- Service d'ophtalmologie, CHU de Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, CRMR OPHTARA (maladies rares en ophtalmologie), 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France
| | - M Labetoulle
- Service d'ophtalmologie, CHU de Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, CRMR OPHTARA (maladies rares en ophtalmologie), 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France; Département d'immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB/IDMIT) CEA, Fontenay-aux-Roses, France
| | - A Rousseau
- Service d'ophtalmologie, CHU de Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, CRMR OPHTARA (maladies rares en ophtalmologie), 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France; Département d'immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB/IDMIT) CEA, Fontenay-aux-Roses, France.
| |
Collapse
|
41
|
Ben Hadj Salah W, Baudouin C, Doan S, Angoulvant A, Gottlieb J, Bénichou J, Da Cunha E, Eid L, Labetoulle M, Rousseau A. [Demodex and ocular surface disease]. J Fr Ophtalmol 2020; 43:1069-1077. [PMID: 33127178 DOI: 10.1016/j.jfo.2020.08.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Revised: 08/08/2020] [Accepted: 08/24/2020] [Indexed: 12/12/2022]
Abstract
Demodex is a saprophytic mite of the ocular adnexa, which can in certain circumstances proliferate on the skin of the face and on the eyelid margins. It is involved in facial rosacea (especially in the papulopustular form) and in the development or aggravation of anterior and/or posterior blepharitis or even keratoconjunctivitis, often in association with cutaneous lesions ; the pathophysiology is often multifactorial. Symptoms are non-specific, but the presence of cylindrical sleeves on the eyelashes is very suggestive of infestation, and certain techniques of biomicroscopic examination or imaging, such as confocal microscopy in vivo, allow direct visualization of the parasite. Parasitological examination of the eyelashes can confirm the diagnosis and can be improved by good sampling technique. Eyelid hygiene and oil-based ointments are the cornerstone of treatment. New specific treatments, in particular topical treatments based on tea tree oil, ivermectin, as well as pulsed light therapy and micro-exfoliation of the eyelid margin, can help to reduce the parasitic load and improve symptoms.
Collapse
Affiliation(s)
- W Ben Hadj Salah
- Service d'ophtalmologie, hôpital Bicêtre, CHU de Bicêtre, Assistance Publique-Hôpitaux de Paris, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, Paris, France
| | - C Baudouin
- Services d'ophtalmologie, CHNO des XV-XX, et hôpital Ambroise-Paré, Assistance Publique-Hôpitaux de Paris, université Versailles-St-Quentin-en-Yvelines, IHU de Sight Restore Saclay, Paris, France; Institut de la vision, Sorbonne université, Inserm, CNRS, Sorbonne, France
| | - S Doan
- Service d'ophtalmologie, CHU de Bichat, Assistance Publique-Hôpitaux de Paris et Fondation ophtalmologique Rothschild, réseau OPHTARA : maladies rares en ophtalmologie, Paris, France
| | - A Angoulvant
- Service de parasitologie, hôpital Bicêtre, CHU de Bicêtre, Assistance Publique-Hôpitaux de Paris, université Paris-Saclay, Paris, France
| | - J Gottlieb
- Service d'immunologie clinique & consultation de dermatologie, hôpital Bicêtre, CHU de Bicêtre, Assistance Publique-Hôpitaux de Paris, université Paris-Saclay, Paris, France
| | - J Bénichou
- Service d'ophtalmologie, hôpital Bicêtre, CHU de Bicêtre, Assistance Publique-Hôpitaux de Paris, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, Paris, France
| | - E Da Cunha
- Service d'ophtalmologie, hôpital Bicêtre, CHU de Bicêtre, Assistance Publique-Hôpitaux de Paris, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, Paris, France
| | - L Eid
- Service d'ophtalmologie, hôpital Bicêtre, CHU de Bicêtre, Assistance Publique-Hôpitaux de Paris, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, Paris, France
| | - M Labetoulle
- Service d'ophtalmologie, hôpital Bicêtre, CHU de Bicêtre, Assistance Publique-Hôpitaux de Paris, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, Paris, France; Département immunologie des maladies virales, auto-immunes, bactériennes et hématologiques (IMVA-HB). UMR 1184, CEA, Fontenay-Aux-Roses, France
| | - A Rousseau
- Service d'ophtalmologie, hôpital Bicêtre, CHU de Bicêtre, Assistance Publique-Hôpitaux de Paris, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, Paris, France; Département immunologie des maladies virales, auto-immunes, bactériennes et hématologiques (IMVA-HB). UMR 1184, CEA, Fontenay-Aux-Roses, France.
| |
Collapse
|
42
|
Poignet B, Rousseau A, Labetoulle M. Intravitreal precipitation of vancomycin and ceftazidime. J Fr Ophtalmol 2020; 44:275-276. [PMID: 33097291 DOI: 10.1016/j.jfo.2020.04.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 04/15/2020] [Indexed: 11/19/2022]
Affiliation(s)
- B Poignet
- Department of Ophthalmology, DHU Vision & Handicaps, French Reference Center for FAP (NNERF), French reference network for rare ophthalmologic diseases (OPHTARA), hôpital Bicêtre, Paris-Sud University, AP-HP, 78, avenue du Général-Leclerc, 94270 Le-Kremlin-Bicêtre, France; Department of Ophthalmology, centre hospitalier national des Quinze-Vingts, Paris, France.
| | - A Rousseau
- Department of Ophthalmology, DHU Vision & Handicaps, French Reference Center for FAP (NNERF), French reference network for rare ophthalmologic diseases (OPHTARA), hôpital Bicêtre, Paris-Sud University, AP-HP, 78, avenue du Général-Leclerc, 94270 Le-Kremlin-Bicêtre, France; Inserm U1184, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), IDMIT Infrastructure, 18, route du Panorama, 92265 Fontenay-aux-Roses cedex, France
| | - M Labetoulle
- Department of Ophthalmology, DHU Vision & Handicaps, French Reference Center for FAP (NNERF), French reference network for rare ophthalmologic diseases (OPHTARA), hôpital Bicêtre, Paris-Sud University, AP-HP, 78, avenue du Général-Leclerc, 94270 Le-Kremlin-Bicêtre, France; Inserm U1184, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB/IDMIT), IDMIT Infrastructure, 18, route du Panorama, 92265 Fontenay-aux-Roses cedex, France
| |
Collapse
|
43
|
Géba E, Rousseau A, Le Guernic A, Escotte-Binet S, Favennec L, La Carbona S, Gargala G, Dubey JP, Villena I, Betoulle S, Aubert D, Bigot-Clivot A. Survival and infectivity of Toxoplasma gondii and Cryptosporidium parvum oocysts bioaccumulated by Dreissena polymorpha. J Appl Microbiol 2020; 130:504-515. [PMID: 32737913 DOI: 10.1111/jam.14802] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Revised: 07/20/2020] [Accepted: 07/23/2020] [Indexed: 01/04/2023]
Abstract
AIMS The study was aimed to understand the depuration process of Cryptosporidium parvum and Toxoplasma gondii oocysts by zebra mussel (Dreissena polymorpha), to consider the use of the zebra mussel as a bioremediation tool. MATERIALS AND METHODS Two experiments were performed: (i) individual exposure of mussel to investigate oocyst transfers between bivalves and water and (ii) in vivo exposure to assess the ability of the zebra mussel to degrade oocysts. RESULTS (i) Our results highlighted a transfer of oocysts from the mussels to the water after 3 and 7 days of depuration; however, some oocysts were still bioaccumulated in mussel tissue. (ii) Between 7 days of exposure at 1000 or 10 000 oocysts/mussel/day and 7 days of depuration, the number of bioaccumulated oocysts did not vary but the number of infectious oocysts decreased. CONCLUSION Results show that D. polymorpha can release oocysts in water via (pseudo)faeces in depuration period. Oocysts remain bioaccumulated and infectious oocyst number decreases during the depuration period in zebra mussel tissues. Results suggest a degradation of bioaccumulated C. parvum and T. gondii oocysts. SIGNIFICANCE AND IMPACT OF THE STUDY This study highlighted the potential use of D. polymorpha as a bioremediation tool to mitigate of protozoan contamination in water resources.
Collapse
Affiliation(s)
- E Géba
- UMR-I 02 SEBIO (Stress Environnementaux et BIOsurveillance des milieux aquatiques), Université de Reims Champagne Ardenne, UFR Sciences Exactes et Naturelles, Reims Cedex 2, France.,EA7510, ESCAPE (EpidémioSurveillance et CirculAtion des Parasites dans les Environnements), Faculté de Médecine, Université de Reims Champagne Ardenne, Reims, France
| | - A Rousseau
- EA7510, ESCAPE (EpidémioSurveillance et CirculAtion des Parasites dans les Environnements), Faculté de Médecine, Université de Reims Champagne Ardenne, Reims, France.,ACTALIA Food Safety Department, Saint-Lô, France
| | - A Le Guernic
- UMR-I 02 SEBIO (Stress Environnementaux et BIOsurveillance des milieux aquatiques), Université de Reims Champagne Ardenne, UFR Sciences Exactes et Naturelles, Reims Cedex 2, France
| | - S Escotte-Binet
- EA7510, ESCAPE (EpidémioSurveillance et CirculAtion des Parasites dans les Environnements), Faculté de Médecine, Université de Reims Champagne Ardenne, Reims, France
| | - L Favennec
- EA7510, ESCAPE (EpidémioSurveillance et CirculAtion des Parasites dans les Environnements), Université de Rouen, Rouen Cedex, France
| | - S La Carbona
- ACTALIA Food Safety Department, Saint-Lô, France
| | - G Gargala
- EA7510, ESCAPE (EpidémioSurveillance et CirculAtion des Parasites dans les Environnements), Université de Rouen, Rouen Cedex, France
| | - J P Dubey
- United States Department Agriculture, Agricultural Research Service, Beltsville Agricultural Research Center, Animal Parasitic Diseases Laboratory, Beltsville, MD, USA
| | - I Villena
- EA7510, ESCAPE (EpidémioSurveillance et CirculAtion des Parasites dans les Environnements), Faculté de Médecine, Université de Reims Champagne Ardenne, Reims, France
| | - S Betoulle
- UMR-I 02 SEBIO (Stress Environnementaux et BIOsurveillance des milieux aquatiques), Université de Reims Champagne Ardenne, UFR Sciences Exactes et Naturelles, Reims Cedex 2, France
| | - D Aubert
- EA7510, ESCAPE (EpidémioSurveillance et CirculAtion des Parasites dans les Environnements), Faculté de Médecine, Université de Reims Champagne Ardenne, Reims, France
| | - A Bigot-Clivot
- UMR-I 02 SEBIO (Stress Environnementaux et BIOsurveillance des milieux aquatiques), Université de Reims Champagne Ardenne, UFR Sciences Exactes et Naturelles, Reims Cedex 2, France
| |
Collapse
|
44
|
Bondu S, Alary AS, Lefèvre C, Houy A, Jung G, Lefebvre T, Rombaut D, Boussaid I, Bousta A, Guillonneau F, Perrier P, Alsafadi S, Wassef M, Margueron R, Rousseau A, Droin N, Cagnard N, Kaltenbach S, Winter S, Kubasch AS, Bouscary D, Santini V, Toma A, Hunault M, Stamatoullas A, Gyan E, Cluzeau T, Platzbecker U, Adès L, Puy H, Stern MH, Karim Z, Mayeux P, Nemeth E, Park S, Ganz T, Kautz L, Kosmider O, Fontenay M. A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome. Sci Transl Med 2020; 11:11/500/eaav5467. [PMID: 31292266 DOI: 10.1126/scitranslmed.aav5467] [Citation(s) in RCA: 52] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2018] [Revised: 03/19/2019] [Accepted: 06/12/2019] [Indexed: 12/21/2022]
Abstract
Myelodysplastic syndromes (MDS) with ring sideroblasts are hematopoietic stem cell disorders with erythroid dysplasia and mutations in the SF3B1 splicing factor gene. Patients with MDS with SF3B1 mutations often accumulate excessive tissue iron, even in the absence of transfusions, but the mechanisms that are responsible for their parenchymal iron overload are unknown. Body iron content, tissue distribution, and the supply of iron for erythropoiesis are controlled by the hormone hepcidin, which is regulated by erythroblasts through secretion of the erythroid hormone erythroferrone (ERFE). Here, we identified an alternative ERFE transcript in patients with MDS with the SF3B1 mutation. Induction of this ERFE transcript in primary SF3B1-mutated bone marrow erythroblasts generated a variant protein that maintained the capacity to suppress hepcidin transcription. Plasma concentrations of ERFE were higher in patients with MDS with an SF3B1 gene mutation than in patients with SF3B1 wild-type MDS. Thus, hepcidin suppression by a variant ERFE is likely responsible for the increased iron loading in patients with SF3B1-mutated MDS, suggesting that ERFE could be targeted to prevent iron-mediated toxicity. The expression of the variant ERFE transcript that was restricted to SF3B1-mutated erythroblasts decreased in lenalidomide-responsive anemic patients, identifying variant ERFE as a specific biomarker of clonal erythropoiesis.
Collapse
Affiliation(s)
- Sabrina Bondu
- Université de Paris, Paris 75006, France.,Institut Cochin, Département Développement, Reproduction, Cancer, Paris 75014, France.,Institut National de la Santé et de la Recherche médicale (INSERM) U1016, Paris 75014, France.,Centre National de la Recherche Scientifique (CNRS) Unité Mixte de recherche (UMR) 8104, Paris 75014, France
| | - Anne-Sophie Alary
- Université de Paris, Paris 75006, France.,Institut Cochin, Département Développement, Reproduction, Cancer, Paris 75014, France.,Institut National de la Santé et de la Recherche médicale (INSERM) U1016, Paris 75014, France.,Centre National de la Recherche Scientifique (CNRS) Unité Mixte de recherche (UMR) 8104, Paris 75014, France.,Service d'hématologie biologique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris Centre-Cochin, Paris 75014, France
| | - Carine Lefèvre
- Université de Paris, Paris 75006, France.,Institut Cochin, Département Développement, Reproduction, Cancer, Paris 75014, France.,Institut National de la Santé et de la Recherche médicale (INSERM) U1016, Paris 75014, France.,Centre National de la Recherche Scientifique (CNRS) Unité Mixte de recherche (UMR) 8104, Paris 75014, France.,Laboratoire d'excellence du Globule Rouge GR-Ex, Paris 75015, France
| | - Alexandre Houy
- Institut Curie, PSL Research University, Human Genetics and Oncogenesis, Paris 75005, France
| | - Grace Jung
- Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Thibaud Lefebvre
- Université de Paris, Paris 75006, France.,Laboratoire d'excellence du Globule Rouge GR-Ex, Paris 75015, France.,INSERM, UMR 1149/ERL CNRS 8252, Centre de Recherches sur l'inflammation, Université de Paris, Paris 75018, France
| | - David Rombaut
- Université de Paris, Paris 75006, France.,Institut Cochin, Département Développement, Reproduction, Cancer, Paris 75014, France.,Institut National de la Santé et de la Recherche médicale (INSERM) U1016, Paris 75014, France.,Centre National de la Recherche Scientifique (CNRS) Unité Mixte de recherche (UMR) 8104, Paris 75014, France
| | - Ismael Boussaid
- Université de Paris, Paris 75006, France.,Institut Cochin, Département Développement, Reproduction, Cancer, Paris 75014, France.,Institut National de la Santé et de la Recherche médicale (INSERM) U1016, Paris 75014, France.,Centre National de la Recherche Scientifique (CNRS) Unité Mixte de recherche (UMR) 8104, Paris 75014, France
| | - Abderrahmane Bousta
- Université de Paris, Paris 75006, France.,Institut Cochin, Département Développement, Reproduction, Cancer, Paris 75014, France.,Institut National de la Santé et de la Recherche médicale (INSERM) U1016, Paris 75014, France.,Centre National de la Recherche Scientifique (CNRS) Unité Mixte de recherche (UMR) 8104, Paris 75014, France
| | - François Guillonneau
- Université de Paris, Paris 75006, France.,Institut Cochin, Département Développement, Reproduction, Cancer, Paris 75014, France.,Institut National de la Santé et de la Recherche médicale (INSERM) U1016, Paris 75014, France.,Centre National de la Recherche Scientifique (CNRS) Unité Mixte de recherche (UMR) 8104, Paris 75014, France.,Proteomic platform 3P5, Université de Paris, Paris 75014, France
| | - Prunelle Perrier
- Institut de Recherche en Santé Digestive (IRSD), Université de Toulouse, INSERM U1220, Institut National de la Recherche Agronomique U1416, Ecole Nationale Vétérinaire de Toulouse, Université Paul Sabatier, Toulouse 31024, France
| | - Samar Alsafadi
- Institut Curie, PSL Research University, Department of Translational Research, Paris 75005, France
| | - Michel Wassef
- Institut Curie, PSL Research University, INSERM 934/UMR 3215, Genetics and biology of Development, Paris 75005 France
| | - Raphaël Margueron
- Institut Curie, PSL Research University, INSERM 934/UMR 3215, Genetics and biology of Development, Paris 75005 France
| | - Alice Rousseau
- Université de Paris, Paris 75006, France.,Institut Cochin, Département Développement, Reproduction, Cancer, Paris 75014, France.,Institut National de la Santé et de la Recherche médicale (INSERM) U1016, Paris 75014, France.,Centre National de la Recherche Scientifique (CNRS) Unité Mixte de recherche (UMR) 8104, Paris 75014, France
| | - Nathalie Droin
- Institut Gustave Roussy, Genomic platform, Villejuif 94805, France
| | - Nicolas Cagnard
- Université de Paris, Paris 75006, France.,Platform Bioinformatics, Université de Paris, Paris 75015, France
| | - Sophie Kaltenbach
- Université de Paris, Paris 75006, France.,Laboratoire de Génétique, AP-HP, Hôpital Necker, Paris 75015, France
| | - Susann Winter
- Medical Clinic und Policlinic 1, Technische Universität Dresden, Dresden 01307, Germany
| | - Anne-Sophie Kubasch
- Medical Clinic und Policlinic 1, Hematology and Cellular Therapy, University Hospital, Leipzig 04103, Germany
| | - Didier Bouscary
- Université de Paris, Paris 75006, France.,Institut Cochin, Département Développement, Reproduction, Cancer, Paris 75014, France.,Institut National de la Santé et de la Recherche médicale (INSERM) U1016, Paris 75014, France.,Centre National de la Recherche Scientifique (CNRS) Unité Mixte de recherche (UMR) 8104, Paris 75014, France.,Service d'Hématologie clinique, AP-HP, Hôpitaux Universitaires Paris Centre-Cochin, Paris 75014, France
| | - Valeria Santini
- MDS unit, Hematology, AOU Careggi, University of Florence, Florence 50134, Italy
| | - Andrea Toma
- Département d'Hématologie, AP-HP, Hôpital Henri-Mondor, Université Paris 12, Créteil 94000, France
| | - Mathilde Hunault
- Service des Maladies du Sang, Centre hospitalo-universitaire, Angers 49100, France
| | | | - Emmanuel Gyan
- Service d'hématologie et thérapie cellulaire, Centre hospitalo-universitaire, CNRS ERL 7001 LNOx, Université de Tours, Tours 37044, France
| | - Thomas Cluzeau
- Côte d'Azur University, CHU of Nice, Hematology department and INSERM U1065, Mediterranean Center of Molecular Medecine, Nice 06204, France
| | - Uwe Platzbecker
- Medical Clinic und Policlinic 1, Hematology and Cellular Therapy, University Hospital, Leipzig 04103, Germany
| | - Lionel Adès
- Université de Paris, Paris 75006, France.,Service d'Hématologie Senior, AP-HP, Hôpital Saint-Louis, Paris 75010, France
| | - Hervé Puy
- Université de Paris, Paris 75006, France.,Laboratoire d'excellence du Globule Rouge GR-Ex, Paris 75015, France.,INSERM, UMR 1149/ERL CNRS 8252, Centre de Recherches sur l'inflammation, Université de Paris, Paris 75018, France
| | - Marc-Henri Stern
- Institut Curie, PSL Research University, INSERM U830, Genetics and biology of cancers, DNA repair and uveal melanoma (D.R.U.M.), Équipe labellisée par la Ligue nationale contre le cancer, Paris 75005, France
| | - Zoubida Karim
- Université de Paris, Paris 75006, France.,Laboratoire d'excellence du Globule Rouge GR-Ex, Paris 75015, France.,INSERM, UMR 1149/ERL CNRS 8252, Centre de Recherches sur l'inflammation, Université de Paris, Paris 75018, France
| | - Patrick Mayeux
- Université de Paris, Paris 75006, France.,Institut Cochin, Département Développement, Reproduction, Cancer, Paris 75014, France.,Institut National de la Santé et de la Recherche médicale (INSERM) U1016, Paris 75014, France.,Centre National de la Recherche Scientifique (CNRS) Unité Mixte de recherche (UMR) 8104, Paris 75014, France.,Laboratoire d'excellence du Globule Rouge GR-Ex, Paris 75015, France.,Proteomic platform 3P5, Université de Paris, Paris 75014, France
| | - Elizabeta Nemeth
- Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Sophie Park
- Département d'Hématologie, Centre Hospitalier Universitaire, Université de Grenoble Alpes, La Tronche 38700, France
| | - Tomas Ganz
- Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Léon Kautz
- Institut de Recherche en Santé Digestive (IRSD), Université de Toulouse, INSERM U1220, Institut National de la Recherche Agronomique U1416, Ecole Nationale Vétérinaire de Toulouse, Université Paul Sabatier, Toulouse 31024, France
| | - Olivier Kosmider
- Université de Paris, Paris 75006, France. .,Institut Cochin, Département Développement, Reproduction, Cancer, Paris 75014, France.,Institut National de la Santé et de la Recherche médicale (INSERM) U1016, Paris 75014, France.,Centre National de la Recherche Scientifique (CNRS) Unité Mixte de recherche (UMR) 8104, Paris 75014, France.,Service d'hématologie biologique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris Centre-Cochin, Paris 75014, France.,Laboratoire d'excellence du Globule Rouge GR-Ex, Paris 75015, France
| | - Michaëla Fontenay
- Université de Paris, Paris 75006, France. .,Institut Cochin, Département Développement, Reproduction, Cancer, Paris 75014, France.,Institut National de la Santé et de la Recherche médicale (INSERM) U1016, Paris 75014, France.,Centre National de la Recherche Scientifique (CNRS) Unité Mixte de recherche (UMR) 8104, Paris 75014, France.,Service d'hématologie biologique, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris Centre-Cochin, Paris 75014, France.,Laboratoire d'excellence du Globule Rouge GR-Ex, Paris 75015, France
| |
Collapse
|
45
|
Rousseau A, Fenolland JR, Labetoulle M. [SARS-CoV-2, COVID-19 and the eye: An update on published data]. J Fr Ophtalmol 2020; 43:642-652. [PMID: 32631687 PMCID: PMC7260525 DOI: 10.1016/j.jfo.2020.05.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2020] [Revised: 05/18/2020] [Accepted: 05/19/2020] [Indexed: 01/08/2023]
Abstract
La pandémie de COVID-19 a bouleversé notre quotidien d’ophtalmologiste. Cette revue générale propose dans un premier temps de mieux faire connaissance avec le virus responsable de la pandémie, le SARS-CoV-2, et des atteintes cliniques du COVID-19. La seconde partie détaille la physiopathologie, les signes cliniques et les enjeux des atteintes oculaires, finalement rares et qui semblent peu sévères sur le plan fonctionnel, mais qui sont potentiellement source de contamination. Enfin, nous abordons les mesures préventives à mettre en place pour éviter toute dissémination virale en consultation d’ophtalmologie.
Collapse
Affiliation(s)
- A Rousseau
- Service d'ophtalmologie, CHU Bicêtre, hôpital Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, Le Kremlin-Bicêtre, France; Département immunologie des maladies virales, auto-immunes, bactériennes et hématologiques. UMR 1184, CEA, Fontenay-Aux-Roses, France.
| | - J-R Fenolland
- Service d'ophtalmologie, hôpital d'instruction des Armées Bégin, Saint-Mandé, France
| | - M Labetoulle
- Service d'ophtalmologie, CHU Bicêtre, hôpital Bicêtre, Assistance publique-Hôpitaux de Paris, université Paris-Saclay, réseau OPHTARA : maladies rares en ophtalmologie, Le Kremlin-Bicêtre, France; Département immunologie des maladies virales, auto-immunes, bactériennes et hématologiques. UMR 1184, CEA, Fontenay-Aux-Roses, France
| |
Collapse
|
46
|
Affiliation(s)
- M Labetoulle
- Service d'ophtalmologie, hôpital de Bicêtre, 78, avenue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France; IDMIT Infrastructure, CEA, Université Paris Sacaly, Inserm U1184, 18, route du Panorama, 92265 Fontenay-aux-Roses cedex, France.
| | - S Doan
- Service d'ophtalmologie, hôpital de Bicêtre, 78, avenue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France; Hôpital Fondation Adolphe de Rothschild, 29, rue Manin, 75019 Paris, France
| | - A Rousseau
- Service d'ophtalmologie, hôpital de Bicêtre, 78, avenue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France; IDMIT Infrastructure, CEA, Université Paris Sacaly, Inserm U1184, 18, route du Panorama, 92265 Fontenay-aux-Roses cedex, France
| |
Collapse
|
47
|
Arndt C, Audrun F, Bodaghi B, Caujolle JP, Cassoux N, Defoort S, Delyfer MN, Denis P, Doan S, Fenolland JR, Giraud JM, Kodjikian L, Labetoulle M, Lasudry J, Leveziel N, Rousseau A, Saadoun D, Speeg-Schatz C, Touhami S, Touitou V, Vignal C, Zech C. [Categorization of the degree of urgency according to ophthalmology procedures or situations]. J Fr Ophtalmol 2020; 43:525-528. [PMID: 32409227 DOI: 10.1016/j.jfo.2020.04.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Accepted: 04/27/2020] [Indexed: 11/19/2022]
Affiliation(s)
- C Arndt
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - F Audrun
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - B Bodaghi
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - J-P Caujolle
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - N Cassoux
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - S Defoort
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - M-N Delyfer
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - P Denis
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - S Doan
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - J-R Fenolland
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - J-M Giraud
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - L Kodjikian
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France.
| | - M Labetoulle
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - J Lasudry
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - N Leveziel
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - A Rousseau
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - D Saadoun
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - C Speeg-Schatz
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - S Touhami
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - V Touitou
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - C Vignal
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| | - C Zech
- Société française d'ophtalmologie, 17, VLA d'Alésia, 75014 Paris, France
| |
Collapse
|
48
|
Serianni G, Toigo V, Bigi M, Boldrin M, Chitarin G, Dal Bello S, Grando L, Luchetta A, Marcuzzi D, Pasqualotto R, Pomaro N, Zaccaria P, Zanotto L, Agostinetti P, Agostini M, Antoni V, Aprile D, Barbisan M, Battistella M, Brombin M, Canton A, Cavazzana R, Dalla Palma M, Dan M, Delogu R, De Lorenzi A, De Muri M, Denizeau S, Fadone M, Fellin F, Ferro A, Gaio E, Gambetta G, Gasparini F, Gnesotto F, Jain P, Maistrello A, Manduchi G, Manfrin S, Marchiori G, Marconato N, Moresco M, Patton T, Pavei M, Peruzzo S, Pilan N, Pimazzoni A, Piovan R, Poggi C, Recchia M, Rigoni A, Rizzolo A, Rostagni G, Sartori E, Siragusa M, Sonato P, Spada E, Spagnolo S, Spolaore M, Taliercio C, Tinti P, Ugoletti M, Valente M, Zamengo A, Zaniol B, Zaupa M, Cavenago M, Boilson D, Rotti C, Veltri P, Chareyre J, Decamps H, Dremel M, Graceffa J, Geli F, Schunke B, Svensson L, Urbani M, Bonicelli T, Agarici G, Garbuglia A, Masiello A, Paolucci F, Simon M, Bailly-Maitre L, Bragulat E, Gomez G, Gutierrez D, Labate C, Mico G, Moreno JF, Pilard V, Kouzmenko G, Rousseau A, Chakraborty A, Baruah U, Patel H, Singh NP, Patel A, Dhola H, Raval B, Cristofaro S, Fantz U, Heinemann B, Kraus W, Kashiwagi M, Tobari H. First operation in SPIDER and the path to complete MITICA. Rev Sci Instrum 2020; 91:023510. [PMID: 32113382 DOI: 10.1063/1.5133076] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2019] [Accepted: 01/22/2020] [Indexed: 06/10/2023]
Abstract
The requirements of ITER neutral beam injectors (1 MeV, 40 A negative deuterium ion current for 1 h) have never been simultaneously attained; therefore, a dedicated Neutral Beam Test Facility (NBTF) was set up at Consorzio RFX (Padova, Italy). The NBTF includes two experiments: SPIDER (Source for the Production of Ions of Deuterium Extracted from Rf plasma), the full-scale prototype of the source of ITER injectors, with a 100 keV accelerator, to investigate and optimize the properties of the ion source; and MITICA, the full-scale prototype of the entire injector, devoted to the issues related to the accelerator, including voltage holding at low gas pressure. The present paper gives an account of the status of the procurements, of the timeline, and of the voltage holding tests and experiments for MITICA. As for SPIDER, the first year of operation is described, regarding the solution of some issues connected with the radiofrequency power, the source operation, and the characterization of the first negative ion beam.
Collapse
Affiliation(s)
- G Serianni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - V Toigo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Bigi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Boldrin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Chitarin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Dal Bello
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - L Grando
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Luchetta
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - D Marcuzzi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - R Pasqualotto
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - N Pomaro
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Zaccaria
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - L Zanotto
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Agostinetti
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Agostini
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - V Antoni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - D Aprile
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Barbisan
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Battistella
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Brombin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Canton
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - R Cavazzana
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Dalla Palma
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Dan
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - R Delogu
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A De Lorenzi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M De Muri
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Denizeau
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Fadone
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - F Fellin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Ferro
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - E Gaio
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Gambetta
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - F Gasparini
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - F Gnesotto
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Jain
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Maistrello
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Manduchi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Manfrin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Marchiori
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - N Marconato
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Moresco
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - T Patton
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Pavei
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Peruzzo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - N Pilan
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Pimazzoni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - R Piovan
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - C Poggi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Recchia
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Rigoni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Rizzolo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Rostagni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - E Sartori
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Siragusa
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Sonato
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - E Spada
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Spagnolo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Spolaore
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - C Taliercio
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Tinti
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Ugoletti
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Valente
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Zamengo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - B Zaniol
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Zaupa
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Cavenago
- INFN-Laboratori Nazionali di Legnaro (LNL), v.le dell'Università 2, I-35020 Legnaro, PD, Italy
| | - D Boilson
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - C Rotti
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - P Veltri
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - J Chareyre
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - H Decamps
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - M Dremel
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - J Graceffa
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - F Geli
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - B Schunke
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - L Svensson
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - M Urbani
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - T Bonicelli
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - G Agarici
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - A Garbuglia
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - A Masiello
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - F Paolucci
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - M Simon
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - L Bailly-Maitre
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - E Bragulat
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - G Gomez
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - D Gutierrez
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - C Labate
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - G Mico
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - J F Moreno
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - V Pilard
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - G Kouzmenko
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - A Rousseau
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - A Chakraborty
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - U Baruah
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - H Patel
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - N P Singh
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - A Patel
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - H Dhola
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - B Raval
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - S Cristofaro
- IPP, Max-Planck-Institut für Plasmaphysik, Boltzmannstraße 2, D-85748 Garching bei München, Germany
| | - U Fantz
- IPP, Max-Planck-Institut für Plasmaphysik, Boltzmannstraße 2, D-85748 Garching bei München, Germany
| | - B Heinemann
- IPP, Max-Planck-Institut für Plasmaphysik, Boltzmannstraße 2, D-85748 Garching bei München, Germany
| | - W Kraus
- IPP, Max-Planck-Institut für Plasmaphysik, Boltzmannstraße 2, D-85748 Garching bei München, Germany
| | - M Kashiwagi
- National Institutes for Quantum and Radiological Science and Technology, 801-1 Mukoyama, Naka, Ibaraki-ken 311-0193, Japan
| | - H Tobari
- National Institutes for Quantum and Radiological Science and Technology, 801-1 Mukoyama, Naka, Ibaraki-ken 311-0193, Japan
| |
Collapse
|
49
|
Berveiller P, Rousseau A, Rousseau M, Bitumba I, Goffinet F, Rozenberg P. Risk of preterm birth in a twin pregnancy after an early‐term birth in the preceding singleton pregnancy: a retrospective cohort study. BJOG 2020; 127:591-598. [DOI: 10.1111/1471-0528.16071] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/13/2019] [Indexed: 11/28/2022]
Affiliation(s)
- P Berveiller
- Department of Obstetrics and Gynaecology Poissy/Saint‐Germain Hospital Poissy France
| | - A Rousseau
- EA 7285 Paris Saclay University Montigny‐Le‐Bretonneux France
- Department of Maieutic Paris Saclay University Montigny‐Le‐Bretonneux France
| | - M Rousseau
- Department of Obstetrics and Gynaecology Poissy/Saint‐Germain Hospital Poissy France
| | - I Bitumba
- Department of Obstetrics and Gynaecology Poissy/Saint‐Germain Hospital Poissy France
| | - F Goffinet
- Department of Obstetrics and Gynaecology Cochin Port‐Royal Hospital Paris France
| | - P Rozenberg
- Department of Obstetrics and Gynaecology Poissy/Saint‐Germain Hospital Poissy France
- EA 7285 Paris Saclay University Montigny‐Le‐Bretonneux France
| |
Collapse
|
50
|
Rousseau A, Azria E, Baumann S, Deneux‐Tharaux C, Senat MV. Do obstetricians apply the national guidelines? A vignette‐based study assessing practices for the prevention of preterm birth. BJOG 2019; 127:467-476. [DOI: 10.1111/1471-0528.16039] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/25/2019] [Indexed: 01/20/2023]
Affiliation(s)
- A Rousseau
- Midwifery Department Versailles Saint Quentin University Montigny‐le‐Bretonneux France
- EA 7285 Versailles Saint Quentin University Montigny le Bretonneux France
| | - E Azria
- Maternity Unit Notre Dame de Bon Secours Paris Saint Joseph Hospital Paris Descartes University Paris France
- National Institute for Health and Medical Research (INSERM) Unit 1153 Obstetrical Perinatal and Paediatric Epidemiology Research Team (EPOPé) Center for Epidemiology and Statistics Sorbonne Paris Cité DHU Risks in Pregnancy Paris University Paris France
| | - S Baumann
- Midwifery Department Versailles Saint Quentin University Montigny‐le‐Bretonneux France
| | - C Deneux‐Tharaux
- National Institute for Health and Medical Research (INSERM) Unit 1153 Obstetrical Perinatal and Paediatric Epidemiology Research Team (EPOPé) Center for Epidemiology and Statistics Sorbonne Paris Cité DHU Risks in Pregnancy Paris University Paris France
| | - MV Senat
- Department of Obstetrics and Gynaecology Bicêtre Hospital AP‐HP Kremlin Bicêtre France
- Paris Sud Paris Saclay University Le Kremlin Bicêtre France
| |
Collapse
|